

# Alaska Board of Pharmacy

## Agenda Item #1



Roll Call/Call to Order

## Alaska Board of Pharmacy Roster

Board Member Name	Initial Appointment	Reappointed	Term End
Ashley Schaber, PharmD	07/01/2021	03/01/2024	03/01/2028
Sylvain Nouvion, PharmD., Ph.D.	05/31/2023		03/01/2027
James Henderson, RPh	03/01/2017	03/01/2021	03/01/2025
Ramsey Bell, RPh	03/01/2022		03/01/2026
Carla Hebert, RPh	01/05/2023	03/01/2024	03/01/2028
Sara Rasmussen, Public Member	03/01/2023		03/01/2027
Dylan Sanders, Pharmacy Technician	10/28/2024		03/01/2028

Name	Position	Committee Membership/Additional Duties
Ashley Schaber	Chair	Statutes and Regulations
James Henderson		Statutes and Regulations, Compounding
Ramsey Bell		Well-Being
Carla Hebert	Vice Chair	Compounding, Well-Being
Sara Rasmussen		Statutes and Regulations, Controlled Substances Advisory Committee Chair
Sylvain Nouvion	Secretary	Statutes and Regulations
Dylan Sanders		

# Alaska Board of Pharmacy

## Agenda Item #2



## Ethics Disclosures

# Alaska Board of Pharmacy

## Agenda Item #3



## Consent Agenda Items



## ALASKA BOARD OF PHARMACY MEETING

### AGENDA

FEBRUARY 20, 2025

Discussion of the following topics may require executive session. Only authorized members will be permitted to remain in the Board/Zoom room during executive session.

#### Board Members:

Ashley Schaber,  
Pharmacist  
(Chairperson)

James Henderson,  
Pharmacist

Carla Hebert,  
Pharmacist

Ramsey Bell,  
Pharmacist

Sylvain Nouvion,  
Pharmacist

Dylan Sanders,  
Pharmacy  
Technician

Sara Rasmussen,  
Public Member

#### Staff:

Michael Bowles,  
Executive  
Administrator

Brigham Perez,  
Records and  
Licensing  
Supervisor

Amy Glenn,  
Licensing  
Examiner

Sarah Jones,  
Licensing  
Examiner

#### Upcoming Meetings:

May 22, 2025  
August 21, 2025  
November 20, 2025

### Meeting Details

Meeting Name: Alaska Board of Pharmacy Quarterly Meeting

Meeting Start Time: 9:00 AM

Meeting Start Date: February 20, 2025

Meeting End Time: 5:00 PM

Meeting End Date: February 20, 2025

Meeting Locations: 1. Board/Staff - Suite 1535, Atwood Building, Anchorage, AK  
2. Zoom for Public Attendees (Limited In-Person Space)

Meeting Registration Link:

[https://us02web.zoom.us/meeting/register/tZUIf-6qrjkeE9BvKcVQnu32ZiLNmvAO\\_KHf](https://us02web.zoom.us/meeting/register/tZUIf-6qrjkeE9BvKcVQnu32ZiLNmvAO_KHf)

Dial ID: 818 8720 2394

Passcode: 756469

### Links

Board of Pharmacy Homepage: [pharmacy.alaska.gov](http://pharmacy.alaska.gov)

Prescription Drug Monitoring Program State page: [pdmp.alaska.gov](http://pdmp.alaska.gov)

## Agenda

1. Roll Call/Call to Order (9:00 - 9:02)
2. Ethics Disclosures (9:02 – 9:03)
3. Consent Agenda Items (9:03 – 9:05)
  - Review/Approve Meeting Agenda
  - Review Lost or Stolen Controlled Substances/DEA 106s
4. Investigations Review (9:05 – 9:45)
  - Holly Handley, Investigator and Greg Gober, Investigator
    - Investigative Report
    - Case Reviews, Confidential - Executive Session
      - 2024-000876
      - 2024-001004
5. Division of Corporations, Business, and Professional Licensing Updates
  - Michael Bowles, Executive Administrator of the Board of Pharmacy (9:45 – 10:30)
    - Annual Reminder - Travel Procedures
    - Discipline Matrix Updates, Confidential - Executive Session
    - Prescription Drug Monitoring Program (PDMP) Updates
  - Melissa Dumas, Administrative Operations Manager (10:30 – 10:45)
    - Budget Report for 2nd Quarter Fiscal Year 2025
6. Public Comment Period (10:45 – 11:00)
7. Industry Updates (11:00 – 11:30)
  - Brandy Seignemartin, PharmD - AKPhA Executive Director and Brittany Keener, PharmD - AKPhA President (11:00 – 11:30)
8. Statutes Discussion (11:30 – 12:30)
  - Current Legislative Matters
9. Adjourn for Lunch (12:30 – 1:00)
10. Roll Call/Call to Order (1:00 – 1:02)
11. Regulations Discussion (1:02 – 2:00)
  - Update on Current Regulation Project
    - Background Checks

- Discuss Regulation Review for Changes Related to Standard of Care Implementation
12. Public Comment Period (2:00 – 2:15)
13. Board Business (2:15 – 4:45)
- NABP Member Forum Follow-up
    - Ramsey Bell - Artificial Intelligence and Regulatory Boards
  - AKPhA Annual Meeting Follow-up
    - Carla Hebert
  - Collaborative Pharmacy Practice
  - The Pharmacists' Patient Care Process (PPCP)
  - Medicaid Cost of Dispensing Survey Letter
  - Adverse Drug Events
  - ACPE Site Visit to UAA Campus
  - Review Strategic Plan and Discuss Prioritization Matrix
  - Annual Report
  - 2025 Upcoming Conference Attendees
    - NABP Committee on Law Enforcement/Legislation, Mount Prospect, IL – March 03-04, 2025
      - Executive Administrator – Michael Bowles
    - Tri-Regulator Symposium and Opioid Regulatory Collaborative Summit, Tyson's Corner, VA – March 06-07, 2025
      - Executive Administrator – Michael Bowles
    - Rx and Illicit Drug Summit, Nashville, TN – April 21-25, 2025
      - PDMP Manager – Lisa Sherrell
      - Executive Administrator – Michael Bowles
      - Chief Investigator – Erika Prieksat
    - NABP Annual Meeting, Ft. Lauderdale, FL – May 13-16, 2025
      - Executive Administrator – Michael Bowles
      - Attending Member – Sylvain Nouvion
  - Tasks List Review and Update
14. Chair Final Comments (4:45 – 5:00)
- Next Quarterly Meeting – May 22, 2025

15. Adjourn (5:00)





# Alaska Board of Pharmacy

## Agenda #3

### DEA 106 Documents

CONFIDENTIAL

# Alaska Board of Pharmacy

## Agenda Item #4



## Investigations Review



**MEMORANDUM**

DATE: February 03, 2025  
TO: Board of Pharmacy  
THRU: Erika Prieksat, Chief Investigator *EP*  
FROM: Greg Gober, Investigator  
RE: Investigative Report for the February 20, 2025 Meeting

The following information was compiled as an investigative report to the Board for the period of November 01, 2024 thru February 03, 2025; this report includes cases, complaints, and intake matters handled since the last report.

Matters opened by the Paralegals in Anchorage and Juneau, regarding continuing education audits and license action resulting from those matters are covered in this report.

**OPEN - 55**

<u>Case Number</u>	<u>Violation Type</u>	<u>Case Status</u>	<u>Status Date</u>
2024-000967	PDMP Violation: Failure to Register	Complaint	10/11/2024

**OUT OF STATE PHARMACY**

2023-000147	Violation of licensing regulation	Investigation	01/19/2024
-------------	-----------------------------------	---------------	------------

**PHARMACIST**

2024-000761	Violation of Profession Statute or Regulation	Intake	08/26/2024
2024-000805	License Application Problem	Intake	09/04/2024
2024-001014	Violation of Profession Statute or Regulation	Intake	10/28/2024
2024-001175	License Application Review/Referral	Intake	12/12/2024

2025-000006	Continuing education	Intake	12/26/2024
2025-000019	License Application Problem	Intake	01/09/2025
2025-000043	License Application Review/Referral	Intake	01/16/2025
2024-000872	PDMP Violation: Failure to Register	Complaint	09/16/2024
2024-000873	PDMP Violation: Failure to Register	Complaint	09/16/2024
2024-000929	PDMP Violation: Failure to Register	Complaint	10/02/2024
2024-000930	PDMP Violation: Failure to Register	Complaint	10/02/2024
2024-001006	PDMP Violation: Failure to Register	Complaint	10/24/2024
2024-001007	PDMP Violation: Failure to Register	Complaint	10/24/2024
2024-001049	PDMP Violation: Failure to Register	Complaint	11/06/2024
2024-001067	PDMP Violation: Failure to Register	Complaint	11/12/2024
2024-001069	PDMP Violation: Failure to Register	Complaint	11/13/2024
2024-001070	PDMP Violation: Failure to Register	Complaint	11/13/2024
2024-001153	PDMP Violation: Failure to Register	Complaint	12/10/2024
2024-001188	PDMP Violation: Failure to Register	Complaint	12/16/2024

#### **PHARMACIST IN CHARGE**

2024-001208	Violation of License Regulation	Complaint	12/23/2024
-------------	---------------------------------	-----------	------------

#### **PHARMACY**

2024-000757	Violation of licensing regulation	Intake	08/23/2024
2024-000802	Unlicensed practice or activity	Intake	09/03/2024
2024-000804	Unlicensed practice or activity	Intake	09/04/2024
2024-000813	License Application Review/Referral	Intake	09/05/2024
2024-000816	Unlicensed practice or activity	Intake	09/05/2024
2024-000821	Unlicensed practice or activity	Intake	09/06/2024
2024-000822	Unlicensed practice or activity	Intake	09/06/2024
2024-000823	Unlicensed practice or activity	Intake	09/06/2024
2024-001104	Violation of License Regulation	Intake	11/18/2024
2024-001147	Action in another state	Intake	12/05/2024
2024-001191	Action in another state	Intake	12/16/2024
2024-001221	Standard of care	Intake	12/30/2024

2025-000062	Violation of License Regulation	Intake	01/27/2025
2025-000065	License Application Review/Referral	Intake	01/23/2025
2024-000769	Unlicensed practice or activity	Complaint	01/22/2025
2024-000852	PDMP Violation: Failure to Register	Complaint	09/10/2024
2024-000857	PDMP Violation: Failure to Register	Complaint	09/11/2024
2024-000939	License Action in Another State	Complaint	12/05/2024
2024-001184	Action in another state	Complaint	12/30/2024
2024-000831	Compliance Inspection	Closed-Intake	

**PHARMACY TECHNICIAN**

2024-001218	Continuing education	Intake	12/18/2024
2024-000876	Violation of licensing regulation	Investigation	11/26/2024
2024-001004	License Application Review/Referral	Investigation	01/06/2025

**WHOLESALE DRUG DISTRIBUTOR**

2024-000726	Violation of licensing regulation	Intake	08/14/2024
2024-000984	License Application Review/Referral	Intake	10/16/2024
2024-001054	Violation of License Regulation	Intake	11/05/2024
2024-001162	Violation of License Regulation	Intake	12/09/2024
2024-001172	Violation of License Regulation	Intake	12/11/2024
2025-000057	License Application Review/Referral	Intake	01/27/2025
2025-000080	Violation of License Regulation	Intake	01/30/2025
2024-000596	Violation of licensing regulation	Complaint	07/10/2024
2024-000624	Violation of License Regulation	Complaint	07/10/2024
2024-000625	Violation of License Regulation	Complaint	07/10/2024

**Closed - 44**

<u>Case #</u>	<u>Violation Type</u>	<u>Case Status</u>	<u>Closed</u>	<u>Closure</u>
---------------	-----------------------	--------------------	---------------	----------------

**OUT OF STATE PHARMACY**

2023-000616	Action in another state	Closed-Investigation	01/14/2025	Advisement Letter
2023-000887	Unlicensed practice or activity	Closed-Investigation	12/23/2024	License Action

**PHARMACIST**

2024-000810	License Application Review/Referral	Closed-Intake	11/01/2024	Review Complete
2024-000998	Standard of care	Closed-Intake	11/21/2024	Incomplete Complaint
2024-001062	License Application Review/Referral	Closed-Intake	12/05/2024	Review Complete
2024-000589	PDMP Violation: Failure to Register	Closed-Complaint	11/18/2024	No Action - No Violation
2024-001131	Prescriptive practice	Closed-Complaint	01/30/2025	No Action - No Violation
2024-000540	PDMP Violation: Failure to Register	Closed-Investigation	12/20/2024	Advisement Letter
2024-000645	Violation of licensing regulation	Closed-Investigation	01/24/2025	Advisement Letter
2024-000693	Violation of licensing regulation	Closed-Investigation	12/12/2024	Advisement Letter
2024-000849	PDMP Violation: Failure to Register	Closed-Investigation	12/12/2024	Advisement Letter
2024-000935	Violation of Profession Statute or Regulation	Closed-Investigation	11/18/2024	Advisement Letter
2024-000962	License Application Review/Referral	Closed-Investigation	12/12/2024	Advisement Letter
2024-000987	License Application Review/Referral	Closed-Investigation	11/20/2024	Advisement Letter
2024-001022	License Application Review/Referral	Closed-Investigation	12/12/2024	Advisement Letter

**PHARMACIST IN CHARGE**

2024-001123	Violation of License Regulation	Closed-Complaint	12/12/2024	No Action - Unfounded
2024-001167	Action in another state	Closed-Investigation	01/24/2025	Advisement Letter

**PHARMACY**

2024-000815	Unlicensed practice or activity	Closed-Intake	11/08/2024	No Action - Unfounded
2024-001157	Violation of License Regulation	Closed-Intake	01/13/2025	Review Complete
2024-000317	Violation of Profession Statute or Regulation	Closed-Complaint	12/30/2024	No Action - No Violation
2024-000889	Violation of licensing regulation	Closed-Complaint	12/23/2024	No Action - Unfounded
2024-000915	Unlicensed practice or activity	Closed-Complaint	12/12/2024	No Action - No Violation
2024-000621	Violation of licensing regulation	Closed-Investigation	11/20/2024	Advisement Letter

2024-001122	Violation of License Regulation	Closed-Investigation	01/24/2025	Advisement Letter
-------------	---------------------------------	----------------------	------------	-------------------

**PHARMACY TECHNICIAN**

2024-000878	Violation of licensing regulation	Closed-Intake	11/05/2024	Review Complete
2024-001061	License Application Problem	Closed-Complaint	01/31/2025	No Action - No Violation
2024-001219	License Application Review/Referral	Closed-Complaint	01/24/2025	Application Withdrawn
2024-000401	Violation of licensing regulation	Closed-Investigation	01/29/2025	Advisement Letter
2024-000647	Violation of licensing regulation	Closed-Investigation	01/31/2025	Advisement Letter
2024-000811	Violation of licensing regulation	Closed-Investigation	11/08/2024	Non Disciplinary Letter of Advisement
2024-001053	License Application Review/Referral	Closed-Investigation	12/12/2024	Advisement Letter
2024-001141	License Application Review/Referral	Closed-Investigation	01/27/2025	Advisement Letter

**WHOLESALE DRUG DISTRIBUTOR**

2024-000867	Violation of licensing regulation	Closed-Intake	11/25/2024	Review Complete
2024-000951	License Application Review/Referral	Closed-Intake	11/25/2024	Review Complete
2024-000950	License Application Review/Referral	Closed-Complaint	11/20/2024	No Action - No Violation
2024-001166	Violation of License Regulation	Closed-Complaint	01/27/2025	No Action - No Violation
2023-001010	Unlicensed practice or activity	Closed-Investigation	01/06/2025	License Action
2024-000433	Violation of licensing regulation	Closed-Investigation	12/23/2024	License Action
2024-000553	Violation of licensing regulation	Closed-Investigation	11/01/2024	Advisement Letter
2024-000588	Violation of licensing regulation	Closed-Investigation	11/20/2024	Advisement Letter
2024-000597	Violation of licensing regulation	Closed-Investigation	11/25/2024	Advisement Letter
2024-000630	Violation of licensing regulation	Closed-Investigation	01/24/2025	Advisement Letter
2024-000646	Violation of License Regulation	Closed-Investigation	01/31/2025	Advisement Letter
2024-000971	License Application Review/Referral	Closed-Investigation	12/05/2024	Advisement Letter

***END OF REPORT***



# Alaska Board of Pharmacy

## Agenda #4

### Investigation Case Documents

CONFIDENTIAL

# Alaska Board of Pharmacy

## Agenda Item #5



## Division Updates

## RENTAL CARS (AAM 60.120)

The State of Alaska supports a mid-size or less car rental. Rental of a car larger than mid-size may be allowed when several travelers are traveling together or circumstances require the use of a larger car. Such situations must also be documented on the completed reimbursement form.

- All car rentals must be reserved and canceled through E-Travel.
- Travelers are generally not authorized to upgrade their rental cars at the airport. If a car upgrade is required for business or safety reasons, provide explanation on completed reimbursement form.
- Travelers are responsible for refueling rental cars prior to returning them to the rental car companies.
- Any liability coverage offered by the car rental company must be declined. If the contracted rental car company is not used where available, the user agency is responsible for any physical damages. The agency can transfer that risk back to the rental car company by selecting the Collision Damage Waiver (CDW) option.

Rental cars may be driven on State business only, and Risk Management self-insurance coverage applies only where the state contracted car is used on State business. State business includes usual travel related activity (restaurants, hotels, etc.), but does not extend to any personal deviations for individual traveler convenience. Refer to [AAM 60.080](#).

If there is damage to any rental car:

- Travelers are cautioned to never accept responsibility or admit liability.
- If the lessor requests information or payment, advise the lessor to contact the Department of Administration, Division of Risk Management.
- If there is personal injury or an accident, telephone the Division of Risk Management as soon as possible.

**To contact Risk Management**  
Call (907) 465-2180 or FAX: (907) 465-3690

## PRIVATELY OWNED VEHICLES (AAM 60.140)

A traveler may use a privately owned vehicle, such as auto, snowmobile, motorcycle, or boat when it has been deemed in the best interest of the State by a department commissioner or designee. The approving official shall be responsible for substantiating that use of a privately owned vehicle is in the State's best interest. The traveler shall receive a mileage reimbursement equal to the miles entered in the mileage form with the established rates published on the Division of Finance web site at: [http://doa.alaska.gov/dof/travel/resource/POV\\_Rate\\_Table.pdf](http://doa.alaska.gov/dof/travel/resource/POV_Rate_Table.pdf)

When a traveler uses a privately owned vehicle, the amount of reimbursement shall be limited to what the lowest available commercial alternative would have cost. Only mileage incurred

while in travel status is reimbursable or when an approving official deems it in the best interest of the State.

[AAM 60.150](#) contains additional requirements specific to the use of privately owned aircraft.

Where travel policies and collective bargaining agreement terms conflict, the terms of the bargaining agreement supersede.

## TRAVEL EXPENSES AND REQUIRED RECEIPTS/DOCUMENTATION (AAM 60.220)

The following shall be attached to the reimbursement form when submitted for final payment:

- Final itinerary
- Itemized commercial lodging facility receipts (short-term per diem)
- Receipts for expenses (though receipts for expenses of \$50.00 or less are not required, they are strongly encouraged - total reimbursement of expenses without receipt is limited to \$75.00 per trip)
- ATM receipt for any cash advances
- Rental car agreement

Reimbursement of unsupported expenses may be disallowed. Fraudulent claims may be subject to disciplinary action.

## THIRD PARTY REIMBURSEMENT (AAM 60.230)

Occasionally, a third party (outside entity) may agree to pay all or a part of a traveler's travel expenses. In such cases, the reimbursement form indicates the third party's involvement in the trip. The traveler is only entitled to reimbursement for travel expenses, per diem or other expense allowances, etc., in accordance with State policies and is to be paid by the State agency for which they are traveling and/or employed. A traveler may not accept honorariums as long as they are traveling for and representing the State.

The third party should be instructed to reimburse the State directly for the travel expenses to reduce potential tax consequences to the traveler. When this is not possible, any third party reimbursement made directly to the traveler for travel expenses, per diem, and/or meal allowances shall be turned over to the traveler's State agency for deposit into the State treasury.

## PER DIEM ALLOWANCE

Per diem is comprised of **two parts**: lodging and M&IE. There are **two types** of per diem, short-term and long-term. The type is based upon the duration and type of lodging facility provided. Brief returns to the duty station for business or personal convenience do not disrupt the long-term status of the trip. Different per diem allowances apply where commercial facilities are not available. Where travel policies and collective bargaining agreement terms conflict, the terms of the bargaining agreement supersede.

A traveler is not entitled to any per diem if provided meals or lodging by the State or a third party with whom the State is conducting business.

Travelers are also not entitled to a lodging allowance if staying in their own dwelling (e.g., second residence), but may be entitled to M&IE on normal workdays.

## LODGING TYPES AND RATES (AAM 60.240)

When overnight lodging is obtained, travelers are entitled to a lodging allowance:

- Short term – actual lodging cost
- Long term - \$45 per night in Alaska; 55% of federal lodging allowance outside Alaska
- Noncommercial - \$30 per night

Long-term lodging accommodations should be provided when the assignment is expected to be longer than 30 days at one location.

## MEALS & INCIDENTAL EXPENSE ALLOWANCE (AAM 60.250)

Meal and incidental expense (M&IE) allowances and prorated M&IE allowances are used when the traveler is in travel status and the travel is of a nature which requires overnight lodging. The M&IE is to cover the cost of meals and necessary incidental expenses including tips, laundry expenses, etc. The appropriate M&IE for a day is the rate prescribed for the community in which the traveler is required to obtain overnight lodging. On the initial date of departure and the final date of arrival back to the duty station, the traveler will receive 75% of the daily M&IE, regardless of the time of departure/arrival.

Where travel policies and collective bargaining agreement terms conflict, the terms of the bargaining agreement supersede.

Occasionally, a traveler is provided with a meal while at a conference or meeting, or as part of a lodging package such as at bed and breakfast inns (and the State is paying for actual lodging costs). It is the responsibility of the traveler to accurately report consumed meals on the Travel Authorization expense report submitted for the M&IE allowance.

**Short-term** - M&IE for Alaska is \$60.00 for a full day in travel status. For rates in the contiguous United States (CONUS), see the federal per diem rates at the link provided on the Division of Finance web page.

**Long-term or noncommercial** - M&IE for Alaska is \$33.00 for a full day in travel status. Outside Alaska is 55% of federal CONUS.

## TAXES RELATED TO TRAVEL (AAM 60.065)

Employees are responsible for making sure State or local sales taxes are not charged when using a State charge card for purchases in Alaska.

# E-TRAVEL OFFICE POCKET GUIDE TO TRAVEL REGULATIONS



For more detailed guidelines,  
Refer to [AAM 60](#) – Travel Policies

The travel regulations are established under [AS 39.20.160](#) to provide approval for travelers on State business and to provide reimbursement for actual and necessary expenses incurred by travelers while traveling on State business. State agencies and travelers are required to comply with these policies whenever traveling on State business and are prohibited from adopting their own policies that differ from statewide policies without the approval of the Commissioner of Administration

The policies apply uniformly to all travelers unless otherwise provided for by a collective bargaining agreement. Whenever there is a conflict between the Alaska Administrative Manual policies and a collective bargaining agreement, the relevant provisions of the collective bargaining agreement supersede.

**E-Travel Office**  
**PO Box 110204**  
**Juneau, AK 99811-0204**

**1-866-762-8728**

**Web Site:**  
[statetravel.alaska.gov](http://statetravel.alaska.gov)

**Revised 01/01/2021**

## TRAVEL DEFINITIONS

**CTS** – Central Travel System account is a State credit card account used for the purchase of transportation such as rental cars, ferry or airline tickets.

**Day Trip** – Local travel or travel that is part of normal duties that does not include overnight lodging. Some examples of local travel or day trips where the traveler is not in travel status include: an inspector driving to various sites outside the normal duty station and troopers while on patrol in assigned territory.

**Duty Station** – The city, town, or village within 50 miles of where the traveler spends the major portion of working time or the place to which the traveler returns on completion of special assignments.

**Lodging Allowance** – Portion of per diem that covers lodging. Generally, the actual cost of the traveler's hotel room unless otherwise stated in individual bargaining unit agreements.

**M&IE** – Meals and incidental expense allowance covers the cost of meals and incidentals such as tips and laundry expenses.

**Other Authorized Expenses** – Other expenses include costs for business telephone calls, parking fees, purchases of supplies, and other charges necessary to conduct the official business function.

**Per Diem Allowance** – Daily payment instead of reimbursement for actual expenses for lodging, meals, and incidental expenses.

**Reimbursement Form** – Support used to document and approve actual cost and details of travel for final reimbursement.

**Residence** – Location of primary dwelling. If the traveler has multiple residences, it is the residence that bears the most logical relationship to the duty station.

**E- Travel Office** – Staffed by the State Travel Manager, this office serves as the liaison between State agencies and the contracted travel agency.

**Ticket Class** – The lowest ticket class on a regularly scheduled airplane, ship, or train that is the most direct route to accomplish the business purpose of the travel.

**Travel Planners** – Individuals within a department that support travelers by making travel arrangements, explaining policies, ensuring travel is approved prior to purchase, and ensuring reimbursement occurs timely after travel is complete.

**Travel Status** – Travel status means traveling outside the boundaries of the duty station and eligible for reimbursement under these policies.

**Traveler** – Anyone traveling on State business. Includes State officials and employees, as well as board or commission members, volunteers, or non-employees. Note that non-employee travel should be paid in accordance with these policies under a professional service contract when appropriate.

**Unauthorized Expenses** – Costs that are not necessary to conduct official State business are not authorized. For example, fines for

traffic or parking violations, lost keys, lost airline tickets or similar expenses are not authorized and will not be reimbursed.

## FIRST STEPS TO STATE TRAVEL Pre-approval (AAM 60.040)

The first step is to contact your travel planner and follow your agency's protocol for requesting travel. Your travel planner will either contact the contracted agency or use E-Travel Online to purchase your trip.

Pre-approval is required for essentials including purpose, destination, departure and return, total cost, and whether a personal deviation is requested. The level of approval depends on the destination. For travel within Alaska, prior approval is required from the traveler's immediate supervisor or designee. Travel to other states, British Columbia, and Yukon Territory requires an additional approval by the department's commissioner or designee. Travel outside the United States requires additional approval by the department's commissioner and the Governor's Office.

## Travel Purchase Policies (AAM 60.050)

Once your trip is approved, your travel planner purchases the travel. You and your travel planner will receive a final itinerary with your transportation, hotel, and car rental information.

Reimbursable travel must be by the most direct route and efficient means. When traveling on State business, travelers must obtain the lowest ticket class fare ([AS 39.20.140](#)) unless:

- lowest ticket class is not available;
- waiting for lowest ticket class would cause a greater cost to the State;
- lowest ticket class is not in the best interest of the State.

## Payment Methods (AAM 60.060)

Payment for transportation should be made using the traveler's State of Alaska One Card (CARD) or the agency's Central Travel System (CTS) account. Airfare with personal portion (companion coupons or deviations) is initially paid by traveler, with State reimbursing the cost of the minimum business itinerary or actual cost, whichever is less.

Within Alaska, payment for actual cost of lodging (not lodging allowances) should be made on the traveler's One Card, agency CTS or direct billed to the State. Payment for lodging allowance (predetermined amount per collective bargaining agreement or AAM for other than short-term) and M&IE should be made with traveler resources. State of Alaska direct payment for lodging is important because of ordinances which exempt State purchases from local sales taxes within Alaska.

## TRAVEL ADVANCES AND REIMBURSEMENTS (AAM 60.070 & 60.210)

An advance of the estimated per diem allowance may be made to a traveler before traveling and is limited to 80% of estimated meals and incidental expenses.

Following the travel, trip costs are summarized and reimbursements calculated. Any amount due the traveler may be electronically deposited into the traveler's bank account. Any amount due the State may be deducted from an employee's paycheck or collected by personal check.

A traveler shall not receive an additional travel advance until the previous trip has been reconciled and closed out.

## INTERRUPTION OR DEVIATION OF TRAVEL FOR TRAVELER CONVENIENCE (AAM 60.080)

Any interruption or deviation from the most direct and efficient means of travel for traveler convenience requires prior approval at the agency level by the appropriate supervisor or designee. Any additional time or expense resulting from an interruption or deviation for traveler convenience shall be borne solely by the traveler. Deviated travel submitted without a proper State Authorized Fare Quote captured at the time of approval will have a financial consequence to the Traveler.

Travelers planning to combine personal and business travel should familiarize themselves with the [Personal Travel FAQs](#) on the travel website. These FAQs cover the following topics:

- Definition of personal travel deviation
- When to use the contracted travel agency or E-Travel Online
- Routing changes and trip extensions
- Requirement for State-authorized fare quotes
- Fees associated with a State-authorized fare quotes
- How much of the cost will be reimbursed (several examples are provided)
- When leave is required
- Personal deviation may affect workers' compensation coverage
- Interruption of personal leave away from the duty station

Voluntary denied boarding compensation, where the traveler voluntarily vacates his/her seat and takes a later flight, may be retained by a traveler. A traveler cannot volunteer for denied boarding on outbound flight unless the traveler has previously approved personal travel for the beginning of the travel period. Nor may a traveler volunteer for denied boarding if it may cause a delay in return to work. By accepting a voluntary bump on the return portion, the traveler puts himself on personal travel rather than State business. **Travel status ends, no further per diem is allowed, and all State insurance coverage ceases for the duration of the trip.** The traveler is responsible for any additional travel expenses caused by the voluntary action.

## UNUSED TRANSPORTATION AND ACCOMMODATIONS (AAM 60.090)

When travelers' plans change, travelers shall release air, car, and hotel reservations within the time limits specified by carriers and hotels. The State shall not reimburse travelers for charges incurred as a result of failure to release accommodations.

Travelers shall submit any unused portion of air or ferry tickets with the reimbursement form. Travel planners may forward unused tickets to the contracted travel agency to process refunds. Fully refundable tickets are automatically refunded after 30 days.

## AIRLINE DELAYS, RESCHEDULING, AND OVERHEADING (AAM 60.100)

When an airline assumes the cost of a traveler's lodging and/or meals due to airline delays or overheading, the traveler shall be paid up to the originally scheduled arrival time. When the airline does not assume the cost of a traveler's lodging and/or meals, the traveler shall be paid in the same manner as the rest of the trip.

Involuntary denied boarding compensation is payable to the State, not to the individual employee. If a traveler is performing official travel and a carrier denies a confirmed reserved seat on a plane, the traveler must submit to the department any payment received for liquidated damages. The traveler must ensure the carrier shows the "State of Alaska" as payee on the compensation. Any such compensation received must be submitted with the reimbursement form.

## EXCESS BAGGAGE (AAM 60.110)

The State will only pay for excess personal and State baggage necessary to carry out official State business. Such baggage shall be transported by the most economical method.

## AIRPORT SHUTTLE, COURTESY VAN, AND TAXI SERVICE (AAM 60.130)

When a traveler in travel status requires transportation either to or from an airport or ferry terminal, an airport shuttle, courtesy van, or taxi service is allowed. When departing on State travel, if a traveler uses a privately owned vehicle for transportation to or from an airport or ferry terminal, the Traveler is allowed mileage and up to seven days of parking reimbursement. The State does not pay tips or Alaska State or local taxes.

## CONTRACTING FOR SUBSISTENCE (AAM 60.260)

The State may enter into agreements with vendors to furnish meals and lodging to travelers when in the best interest of the State.

## Board Member Travel Procedures

Board members must utilize division staff to book their travel through the state travel contractor's online system. This will allow board members to travel without worrying about booking their own itineraries in accordance with state policy, personally fronting costs associated with airfare on their personal credit cards or wondering whether their costs will be reimbursed. Most itineraries will receive discounted rates because of state-negotiated contracts with Alaska Airlines and other hotel and car rental partners.

### Steps in Planning Your Official Travel Itinerary

1. To initiate this process, the board needs to establish that this expenditure is supported by the board. Please ensure your board has done the following at least six weeks before the date of travel:
  - a. Include the meeting, conference, or event in the board's Annual Report. Often, travel requests are to the same (or similar) events each year. Since there is not enough travel expenditure authority provided by the legislature for every board to take all the trips they may want, only the highest-ranked trips are likely to be approved. While the board may not know all the details months ahead of time, they may know the name of the conference sponsor and event, such as "Annual Educational Conference sponsored by the Council on Licensing, Enforcement, and Regulation." That would be important to include in the Annual Report.
  - b. Vote in a meeting to affirm the board's intent to send representatives to the event, and place on the record a ranked list of who those people are. This may include one or more board members and/or staff. A board member who was not endorsed by the board may be approved by the chair. This may displace one of the members who intended to travel. (Usually, this occurs when someone is no longer able to travel and someone is encouraged to attend in their place.)
2. Following the board meeting where the business reason for travel was discussed and travelers were approved, your board staff will complete a Travel Approval Request Form that explains the business reason for travel, requested travelers, and all known travel details. Approval from the division, department, and sometimes the governor's office is required.
3. Each traveler must complete the Travel Reservation Form for Board Members (attached). This helps us know important details like your Mileage Pan number, whether you prefer an aisle or window seat, and what hotel you prefer for your stay. Email this form to the Travel Desk XXXXXXXXXXXXXXXXXXXX.
4. Ensure the forms required by the state or federal government for reimbursement and per diem (attached) have been completed and returned to the proper agency listed on the form. Do not send to your board staff.
  - a. Substitute Form W-9 (TIN Verification)
  - b. Electronic Payment Agreement

The Electronic Payment Agreement is required only if you wish to receive your per diem and reimbursement electronically. Also, be advised the Internal Revenue Service requires the State of Alaska to issue 1099 forms when payments to individuals, partnerships, or limited liability companies for rents, services, prizes, and awards meet or exceed \$600.00 for the year.

5. Your travel planner will discuss any questions or concerns with you, then finalize the form according to the information you have provided in accordance with state policies. The travel approval will be emailed to you once it has final approval. There is no opportunity for personal deviation using this booking method. If you wish to deviate from the minimum business itinerary, staff should include this request in the initial travel approval request. Be sure you discuss with staff at the Travel Desk once you have received approval to travel.
6. The itinerary, including airline, hotel, and rental car confirmation numbers, will be emailed to you when booked. Staff will also provide the hotel with instruction to bill the division's credit card; however, since hotels must ensure they bill the proper party, the traveler must ensure that they were not charged for the room or taxes. Travelers are required to get a copy of the hotel receipt, even if they do not pay for the stay. Travelers may still be requested to provide a credit card for any room incidentals, such as movies, room service, telephone calls, etc., which are not covered by the state.
7. Turn in all receipts to the division within five days of trip completion to begin the reimbursement process. Any expenses not covered up front will be processed directly to the traveler's bank account once the traveler has completed all the forms mentioned in #4, above.
8. Once travel receipts have been reconciled, an estimated reimbursement e-mail will be sent to the traveler asking them to approve the expenses. Travelers must respond in order for the travel process to be completed and the traveler reimbursed.

### **Booking Travel Through a Third Party**

When associations are able to directly arrange travel for the division board members or staff, there are a few simple steps required to accept their offer:

1. Follow steps 1-5 above. Board members cannot make their own travel arrangements without first being approved to travel. Confer with the Travel Desk to ensure accurate coordination among parties.
2. Turn in all receipts to the division within five days of trip completion to begin the reimbursement process. Any expenses not covered up front will be processed directly to the traveler's bank account. Receipts are needed to track the amount of travel that is being covered by a third party for audit and ethics purposes.

### **Reimbursement of Qualifying Expenses by a Third Party**

Occasionally, an association will offer to reimburse the traveler for expenses incurred while on state business. For example, the profession's national organization may pay a \$1000 stipend to cover the cost of travel to the conference. Or, the association will pay all the airfare and hotel expenses for new board members.

This offer may be accepted under a few conditions:

1. Program staff must follow up with the association once the travel has been reconciled to ensure proper reimbursement occurs.
2. Checks may only be written and mailed to the State of Alaska, addressed to the division. Board members may not accept payment or reimbursement for any purpose and must immediately endorse any payment of this kind

over to the division travel desk for receipting. Reimbursement for authorized expenses will be issued by the State of Alaska.

3. The legislature typically authorizes a small amount of authority for the division to receive third-party travel reimbursements; these are credited to the board that incurred the expense. Any reimbursements over the authorized amount will be reported but not available to the boards to expend. This tracking is important as it may demonstrate the boards' ability to collect receipts above the authorized limit and allow the division to advocate for additional budget authority in future years.

---

If you have questions about a specific scheduled trip or reimbursement, please contact the Travel Desk at [REDACTED]

## Frequently Asked Questions About Travel

### Before Traveling:

**Q: I would like the travel planners to book my travel. What do they need to know before they can book?**

A: We will need the following information:

- Your name as it is written on a government issued form of identification
- Your birthdate
- Your mileage plan number, if any
- A preferred hotel in the city to which you are traveling
- A valid e-mail address so the travel itinerary can be sent to you
- An agenda for the meeting or conference—even a draft is helpful

**Q: When you book my travel, what are the rules?**

A: All state travel rules apply, regardless of whether we act as your agent. However, booking your flight, hotel, rental car, or other travel is a commitment through the state travel agency. So, keep in mind that non-business-related changes and no-shows may result in additional fees, and you may be asked to reimburse the state for those types of avoidable fees.

Unless it has been pre-approved, we can only book the minimum business itinerary. This means that only the lowest ticket class fare for the most direct route will be purchased. We cannot book travel for spouses or other guests. We also will generally only use approved State of Alaska vendors, as we will get the best state negotiated deals on hotels, airfare, and rental cars. This means lower travel expenses for your licensing program.

*Alaska Statute 39.20.140(b) requires that the state pay no more than "the lowest ticket class fare for the most direct route." (AAM 60.050)*

**Q: If you book my hotel but the hotel asks to see the credit card, what should I do?**

A: You can have the hotel call one of your travel planners to confirm the credit card number with them. Your travel planners are available Monday-Friday 8:00am- 5:00pm at either [REDACTED]. You may be asked

to provide a personal card for incidentals, since the state will not pay for amenities such as room service, tips, mini-bar, etc.

**Q: I want to mix my board business trip with pleasure. How can I do this?**

Regardless of who books the travel, we need to know if you are deviating from the business itinerary before your trip is submitted for division approval. Please let the Travel Desk or your board staff know if you are deviating as soon as the meeting is being planned. If your original travel plans change, please let your program staff know as soon as possible so they can request reapproval of the trip. If the cost of personal itinerary is greater than the cost of the minimum business itinerary, you need to book the trip yourself and work with the Travel Desk for reimbursement of qualifying business expenses.

Unapproved deviation from the minimum business itinerary may result in additional costs that you were not anticipating, and the state cannot cover that portion of your travel expenses. For example, if the board meeting ends at 2:00 p.m. and you want to stay in Anchorage until the following afternoon, you will be responsible for the hotel, meals, and difference in flight cost. Any rental cars approved for state business use must be turned in at the time of the first flight after the meeting ends. Keeping the car longer may incur personal expenses, and you may not be covered in case of an accident.

If you are planning your own travel, we still need to know the difference in prices between the business itinerary and the deviation that you are taking before you travel. Please provide your board staff with a flight itinerary for both the business itinerary and the deviation. If we do not receive the business itinerary, the travel planner will obtain a quote for the lowest fare currently available. This may result in a lower reimbursement than you were expecting.

**Q: What are the rules for renting a car when I travel for the state?**

A: When necessary, the rental of a car may be authorized for travelers in travel status according to the minimum business itinerary for the trip. The estimated cost for the rental car must be included in the approval request prior to travel. The cost and intended use of the car must be considered in determining the size and type of car to rent. The State of Alaska supports a mid-size or smaller car rental. Rental of a car larger than mid-size may be allowed when several travelers are traveling together or circumstances require the use of a larger car. Such situations must also be documented on the completed travel authorization. Planning ahead is recommended.

When a rental car is desired, but not required for state business, it is considered personal deviation. A traveler who submits a receipt for a rental car will receive reimbursement for ground transportation for the minimum business itinerary.

**Q. I don't want to stay at the hotel that is closest to the meeting location. What are my options?**

A. You will be booked at a state-contracted hotel that most closely meets the meeting's minimum business itinerary. There are often several hotels close to the facilities most used for meetings—the Atwood Building in Anchorage and the State Office Building in Juneau.

If you prefer to stay at a hotel outside of walking distance, we will book the hotel mentioned in your written request as long as it has a contract with the state and is under \$300 per night. You will be responsible for any amount over the standard hotel. If it requires one, a rental car or taxi between the hotel and meeting location will be considered



personal deviation, and you will be responsible for any amount over the customary ground transportation. If it is unsafe or impractical to walk due to weather, darkness, or other situations, ground transportation will be reimbursed.

**Q. I want to stay an extra day at the meeting location. Can you still book my flight?**

A. Yes, and the difference in cost will be deducted from your reimbursement. If the difference is over \$100, then you may opt to purchase your own ticket and receive reimbursement for the flight listed in the minimum business itinerary.

**After Traveling:**

**Q: What documentation do I need to turn in to be reimbursed?**

A: Board staff can provide you with a travel reimbursement envelope to help keep your receipts together. Because you are paid a state Meals and Incidental Expenses (M&IE) rate, you do not need to submit meal receipts unless a third-party reimbursement agreement requires it.

Within **FIVE** days of completion of travel, please submit:

- Airport receipt and boarding passes or actual itinerary
- Hotel receipt(s)
- Taxi receipt(s)
- Rental car receipt(s)
- Parking receipt(s)
- If you went to a conference, we will need a final meeting agenda and a registration fee receipt (if you paid for it).

**Q: What if I do not have a receipt for my taxi ride?**

A: You will be reimbursed up to \$75 for any qualified expense without a receipt. This means if you took a taxi to the airport and back but forgot to get a receipt, you will only get \$75 total for the entire trip. Most taxis cost around \$20-\$30 one way, so it is always a good idea to remember to get the receipt. Please note that taxis for food and entertainment are not reimbursable—only transportation to/from the meeting location or hotel and airport.

**Q: The state booked my travel. Do I still need to get a hotel receipt?**

A: Yes, we still need to make sure there were only charges that the state allows to be made on the state credit card. If a third party is paying for the hotel, we will still need a receipt to track those expenses for audit and ethics purposes. Please remember that if you had the state book your travel, there should be no taxes on the bill when traveling within Alaska. Check to ensure that room service, mini-bar, fitness, or other hotel charges are not settled to the state credit card. Look over the hotel receipt carefully before checking out and ask for the bill to be split, if necessary.

**Q: What is “mileage,” and why do you need my physical address?**

A: You are eligible to request reimbursement for the mileage between your house or place of work to the airport and back if you live more than 50 miles from the airport/meeting location. In order to give you the correct mileage, we need the physical address of your house or place of work so that we can have an accurate calculation. Please make sure to include a note with your receipts if you drove to the airport from a different location than you usually do so that we can give you the correct reimbursement for mileage.

**Q: I drove to the board meeting. Why am I not getting reimbursed for all the mileage between locations?**

A: If the amount of the mileage is greater than what a plane ticket would cost, you will only be reimbursed for the amount of the minimum business itinerary plane ticket. Also, reimbursement is only available to/from your “duty station,” which is the city in which you claim as your primary location. So, if you are driving (or flying) from a different location, you will receive reimbursement for the lesser of the two legs. For example: If you live in Anchorage but are flying to a Fairbanks meeting while on vacation in Seattle, you will only receive reimbursement for the value of the ANC-FAI flight, unless your actual expense is lower.

**Q: I live in the city that the board is meeting in. What am I reimbursed?**

A: You may request reimbursement for meals for the time when you are at the board meeting, which is typically lunch. You are also reimbursed for parking if applicable, but remember to get a receipt. Please remember to give the travel planner your exact physical address so you are reimbursed accurately.

**Q: I took a trip where part of the travel is being booked or reimbursed by a third party. What do I need to turn in?**

A: We need to know the amount the third party paid for airfare and hotel and need all the receipts for travel even if some or all expenses are being paid for by a third party. This is required for state auditing purposes. All expenses must be settled between the Travel Desk and the third party after your travel has been finalized. Board members are not allowed to accept payment from third parties. All payments must be made to the State of Alaska, and any checks to board members must be turned in to the office immediately. Please do not submit receipts directly to the third party; division staff will handle this.

**Q: How do I know how much per diem I will be reimbursed?**

A: Per diem is determined by the minimum business itinerary and how long you are in travel status during mealtime portions of the day (see chart below). If you are traveling in-state, you will be reimbursed using the state authorized per diem (also called M&IE) rate. If you travel out of state, you will receive the federal rate for your destination. The first and last days of travel will be paid a flat 75% of the daily per diem.

**Q: I was only able to attend the meeting for a few hours. Will I be reimbursed?**

A: To be eligible, you must be in travel status during the meal allowance period for at least three consecutive hours to receive reimbursement for that meal and the daily incidental amount.

**Other Questions:**

**Q: I am a volunteer—not an employee of the State of Alaska. Why do I need to follow your rules?**

A: Board and commission members are appointed by and serve at the pleasure of the Governor. When you are performing board business, you represent the State of Alaska. When you travel for the State of Alaska, you are treated like an employee and thus must follow the same rules that an employee must follow.

*The travel policies of the State of Alaska are adopted by the Commissioner of the Department of Administration in accordance with AS 39.20.160. State agencies and Travelers are required to comply with these policies whenever traveling on state business and are prohibited from adopting their own policies that differ from statewide policies without the approval of the Commissioner of Administration. (AAM 60.010)*

**Q: How do I know that the trip I want to take is “state business”?**

The term “state business” applies when the purpose of the trip can be reasonably related to the person’s role as a board member. This relationship may not always appear black-and-white, such as traveling to represent the board as a delegate. The division will look for elements such as whether the event that is primarily marketed to or attended by members of state boards; whether the board member would otherwise be attending if not for his or her service on the board; and other reasonable connections between board service and the event.

**Q: Travel planners use a lot of terms that I do not know. What do they mean?**

A: Here is a list of commonly used terms that are used for travel:

- Travel Planner: Individuals within each department that support travelers by making travel arrangements, explaining policies, ensuring travel is approved prior to purchase, and ensuring reimbursement occurs timely after travel is complete.
- Traveler: A person employed by the state, a board member, or volunteer that travels for state business outside their duty station.
- M&IE: Meals and incidental expense allowance. Incidental expense includes tips and other personal costs of travel. Also known as *per diem*.
- Residence: The location, or within 50 miles thereof, where the traveler maintains their primary dwelling.
- Duty Station: The city, town, or village within 50 miles of where the traveler spends the major portion of their working time.
- Travel Authorization (TA): The form that must be completed to show travel related expenses. This is completed by the travel planner.
- Minimum Business Itinerary: Travel plans that fit with the state-authorized business trip, without any personal travel.

**Q: Where can I find more information on travel?**

A: We are glad you asked! Please visit <http://doa.alaska.gov/dof/travel/index.html>. Here you can find more FAQs and all of the travel policies you may ever want to know. The best way to contact any of the planners at the division Travel Desk is by e-mailing [REDACTED]

# Alaska Board of Pharmacy

## Agenda #5

### Discipline Matrix Documents

CONFIDENTIAL

# ALASKA


## PRESCRIPTION DRUG MONITORING PROGRAM Q4 2024

### 77,247 PATIENTS

Alaskan patients receiving at least one controlled substance prescription.


### 8,810 REGISTERED USERS

% registered by license type, excluding IHS, military, VA, and delegates.



### 266,149 SEARCHES

% of searches by user type, excluding IHS, military, VA, and delegates.



### 84% EHR ACCESS


% of providers using electronic health record system (EHR) integration to search patient information within their clinical workflow.

### 254 DISPENSERS

Pharmacies or dispensing providers with at least one controlled substance dispensation to Alaska patients.


Data is presented for informational purposes only. Data represents prescription and dispensation activity reported to Alaska Prescription Drug Monitoring Program (PDMP) from October 1, 2024 to December 31, 2024. For more information, visit [pdmp.alaska.gov](http://pdmp.alaska.gov).

# 191,924 CONTROLLED SUBSTANCE DISPENSATIONS




### 19 PARTNER STATES

Interstate data sharing including military health system.



## PRESCRIPTION COUNT BY PATIENT AGE & GENDER



Department of Commerce, Community, and Economic Development  
Division of Corporations, Business and Professional Licensing

Department of Commerce Community, and Economic Development  
Corporations, Business and Professional Licensing

Summary of All Professional Licensing  
Schedule of Revenues and Expenditures

Board of Pharmacy	FY 18	FY 19	Biennium	FY 20	FY 21	Biennium	FY 22	FY 23	Biennium	FY 25	
										FY 24	1st & 2nd QTR
<b>Revenue</b>											
Revenue from License Fees	\$ 801,317	\$ 213,770	\$ 1,015,087	\$ 631,105	\$ 1,121,447	\$ 1,752,552	\$ 444,975	\$ 1,169,195	\$ 1,614,170	\$ 1,256,105	\$ 180,915
General Fund Received					\$ -	-	\$ 29,810	\$ 7,668	37,478	\$ 120,240	\$ -
Allowable Third Party Reimbursements	210	962	1,172	\$ -	\$ -	-	\$ 1,650	\$ 1,500	3,150	\$ 1,588	\$ 396
<b>TOTAL REVENUE</b>	<b>\$ 801,527</b>	<b>\$ 214,732</b>	<b>\$ 1,016,259</b>	<b>\$ 631,105</b>	<b>\$ 1,121,447</b>	<b>\$ 1,752,552</b>	<b>\$ 476,435</b>	<b>\$ 1,178,363</b>	<b>\$ 1,654,798</b>	<b>\$ 1,377,933</b>	<b>\$ 181,311</b>
<b>Expenditures</b>											
Non Investigation Expenditures											
1000 - Personal Services	204,727	194,745	399,472	199,334	278,612	477,946	284,719	335,119	619,838	411,918	247,475
2000 - Travel	13,704	8,299	22,003	2,641	-	2,641	6,363	14,252	20,615	11,602	2,251
3000 - Services	21,960	27,781	49,741	45,283	46,180	91,463	29,584	20,174	49,758	27,965	5,678
4000 - Commodities	-	26	26	521	-	521	82	90	172	300	-
5000 - Capital Outlay	-	-	-	-	-	-	-	-	-	-	-
Total Non-Investigation Expenditures	240,391	230,851	471,242	247,779	324,792	572,571	320,748	369,635	690,383	451,784	255,404
Investigation Expenditures											
1000-Personal Services	68,679	69,997	138,676	57,738	106,494	164,232	94,519	128,331	222,850	188,437	121,131
2000 - Travel	-	-	-	1,260	-	1,260	5,221	3,182	8,403	-	3,191
3023 - Expert Witness	-	-	-	-	-	-	-	-	-	-	-
3088 - Inter-Agency Legal	-	3,062	3,062	2,537	1,269	3,806	12,011	10,018	22,029	1,739	1,398
3094 - Inter-Agency Hearing/Mediation	-	-	-	694	152	846	1,758	68	1,826	15,943	-
3000 - Services other	-	400	400	269	216	485	338	545	883	675	124
4000 - Commodities	-	-	-	-	-	-	-	10	10	-	-
Total Investigation Expenditures	68,679	73,459	142,138	62,498	108,131	170,629	113,847	142,155	256,001	206,794	125,844
<b>Total Direct Expenditures</b>	<b>309,070</b>	<b>304,310</b>	<b>613,380</b>	<b>310,277</b>	<b>432,923</b>	<b>743,200</b>	<b>434,595</b>	<b>511,790</b>	<b>946,384</b>	<b>658,578</b>	<b>381,248</b>
Indirect Expenditures											
Internal Administrative Costs	150,986	155,128	306,114	164,443	191,897	356,340	182,236	190,056	372,292	204,294	102,147
Departmental Costs	78,139	81,374	159,513	58,131	75,431	133,562	76,951	76,872	153,823	102,391	51,196
Statewide Costs	30,555	27,069	57,624	33,868	52,856	86,724	47,667	50,400	98,067	58,103	29,052
<b>Total Indirect Expenditures</b>	<b>259,680</b>	<b>263,571</b>	<b>523,251</b>	<b>256,442</b>	<b>320,184</b>	<b>576,626</b>	<b>306,854</b>	<b>317,328</b>	<b>624,182</b>	<b>364,788</b>	<b>182,395</b>
<b>TOTAL EXPENDITURES</b>	<b>\$ 568,750</b>	<b>\$ 567,881</b>	<b>\$ 1,136,631</b>	<b>\$ 566,719</b>	<b>\$ 753,107</b>	<b>\$ 1,319,826</b>	<b>\$ 741,449</b>	<b>\$ 829,118</b>	<b>\$ 1,570,566</b>	<b>\$ 1,023,366</b>	<b>\$ 563,643</b>
<b>Cumulative Surplus (Deficit)</b>											
Beginning Cumulative Surplus (Deficit)	\$ 275,216	\$ 507,993		\$ 154,844	\$ 219,230		\$ 587,570	\$ 322,556		\$ 671,801	\$ 1,026,368
Annual Increase/(Decrease)	232,777	(353,149)		64,386	368,340		(265,014)	349,245		354,567	(382,332)
Ending Cumulative Surplus (Deficit)	\$ 507,993	154,844		\$ 219,230	\$ 587,570		\$ 322,556	\$ 671,801		\$ 1,026,368	\$ 644,036
<b>Statistical Information</b>											
Number of Licenses for Indirect calculation	5,680	6,203		5,934	6,917		6,542	6,428		6,856	
<b>Additional information:</b>	<ul style="list-style-type: none"> <li>• General fund dollars were received in FY21-FY24 to offset increases in personal services and help prevent programs from going into deficit or increase fees.</li> <li>• Most recent fee change: New fee FY24 (retired)</li> <li>• Annual license fee analysis will include consideration of other factors such as board and licensee input, potential investigation load, court cases, multiple license and fee types under one program, and program changes per AS 08.01.065.</li> </ul>										

Department of Commerce Community, and Economic Development  
Corporations, Business and Professional Licensing

Summary of All Professional Licensing  
Schedule of Revenues and Expenditures

Appropriation Name (Ex)	(Multiple Items)
Sub Unit	(All)
PL Task Code	PHA1

Sum of Budgetary Expenditures Object Name (Ex)	Object Type Name (Ex) 1000 - Personal Services	2000 - Travel	3000 - Services	Grand Total
1011 - Regular Compensation	193,187.21			193,187.21
1014 - Overtime	2.30			2.30
1021 - Allowances to Employees	180.00			180.00
1023 - Leave Taken	28,418.99			28,418.99
1028 - Alaska Supplemental Benefit	13,616.53			13,616.53
1029 - Public Employee's Retirement System Defined Benefits	66.67			66.67
1030 - Public Employee's Retirement System Defined Contribution	11,599.29			11,599.29
1034 - Public Employee's Retirement System Defined Cont Health Reim	7,677.03			7,677.03
1035 - Public Employee's Retirement Sys Defined Cont Retiree Medical	1,837.00			1,837.00
1037 - Public Employee's Retirement Sys Defined Benefit Unfnd Liab	38,121.89			38,121.89
1040 - Group Health Insurance	58,192.27			58,192.27
1041 - Basic Life and Travel	10.10			10.10
1042 - Worker's Compensation Insurance	1,209.08			1,209.08
1047 - Leave Cash In Employer Charge	5,119.23			5,119.23
1048 - Terminal Leave Employer Charge	3,545.88			3,545.88
1053 - Medicare Tax	3,032.25			3,032.25
1062 - GGU Business Leave Bank Contributions	354.49			354.49
1077 - ASEA Legal Trust	210.76			210.76
1079 - ASEA Injury Leave Usage	32.90			32.90
1080 - SU Legal Trst	85.56			85.56
1970 - Personal Services Transfer	2,106.80			2,106.80
2000 - In-State Employee Airfare		1,140.31		1,140.31
2001 - In-State Employee Surface Transportation		799.29		799.29
2002 - In-State Employee Lodging		951.39		951.39
2003 - In-State Employee Meals and Incidentals		300.00		300.00
2006 - In-State Non-Employee Surface Transportation		21.75		21.75
2008 - In-State Non-Employee Meals and Incidentals		212.00		212.00
2009 - In-State Non-Employee Taxable Per Diem		96.00		96.00
2010 - In-State Non-Employee Non-Taxable Reimbursement		1,200.75		1,200.75
2013 - Out-State Employee Surface Transportation		76.13		76.13
2015 - Out-State Employee Meals and Incidentals		118.50		118.50
2020 - Out-State Non-Employee Meals and Incidentals		128.25		128.25
2022 - Out-State Non-Employee Non-Taxable Reimbursement		81.00		81.00
2970 - Travel Cost Transfer		316.82		316.82
3000 - Training/Conferences			1,300.00	1,300.00
3035 - Long Distance			38.59	38.59
3036 - Local/Equipment Charges			1.34	1.34
3045 - Postage			177.10	177.10
3085 - Inter-Agency Mail			4.83	4.83
3088 - Inter-Agency Legal			5,677.43	5,677.43
<b>Grand Total</b>	<b>368,606.23</b>	<b>5,442.19</b>	<b>7,199.29</b>	<b>381,247.71</b>

# Alaska Board of Pharmacy

## Agenda Item #6



Public Comment Period



# Alaska Board of Pharmacy

## Agenda Item #7



## Industry Updates

# Industry Update

---

Brandy Seignemartin, PharmD  
AKPhA Executive Director

&

Brittany Keener, PharmD, MPH, BCPS, FAKPhA  
AKPhA President



# 59<sup>th</sup> Annual Convention & Tradeshow

---

- Three full days of CE and programming
- Over 150 pharmacist, technician, and student pharmacist attendees
- AKPhA Leadership Transition
  - Brittany Keener, AKPhA President
- Thank you for BOP & PDMP participation!



# Current Issues

---

## Medicaid Cost of Dispensing (COD) Survey Results

- In December results presented show decreased COD since 2019
- 71% of survey inputs = staffing
- Potential patient safety & healthcare access issues brewing due to downward pressure on system
- Recap of AKPhA Meeting with Medicaid



# Current Issues

---

## Highlights from the [FTC Second Interim Staff Report on PBMs](#):

- **Significant price markups:** The Big 3 PBMs imposed *markups of hundreds and thousands of percent on numerous specialty generic drugs* dispensed at their affiliated pharmacies—including drugs used to treat cancer, HIV, and other serious diseases and conditions. The Big 3 PBMs also reimbursed their affiliated pharmacies at a higher rate than they paid unaffiliated pharmacies on nearly every specialty generic drug examined.
- **Dispensing the most profitable drugs:** A larger, disproportionate share of commercial prescriptions for specialty generic drugs marked up more than \$1,000 per prescription were dispensed by the Big 3 PBMs' affiliated pharmacies compared with unaffiliated pharmacies. Dispensing patterns suggest that the Big 3 PBMs may be steering highly profitable prescriptions to their own affiliated pharmacies (and away from unaffiliated pharmacies).
- **Over \$7.3 billion of dispensing revenue in excess of NADAC:** The Big 3 PBMs' affiliated pharmacies generated over \$7.3 billion of dispensing revenue in excess of their estimated acquisition cost, as measured by the National Average Drug Acquisition Cost (NADAC), on specialty generic drugs over the study period. PBM-affiliated pharmacy dispensing revenue in excess of NADAC increased dramatically at a *compound annual growth rate of 42 percent* from 2017-2021. In the aggregate, the *top 10 specialty generic drugs generated \$6.2 billion of dispensing revenue in excess of NADAC* (85 percent of total).



# Current Issues

---

## Highlights from the [FTC Second Interim Staff Report on PBMs \(Continued\)](#):

- **Generating additional income via spread pricing:** In the aggregate, the Big 3 PBMs also separately generated an estimated \$1.4 billion of income from spread pricing—i.e., billing their plan sponsor clients more than they reimburse pharmacies for drugs—on the analyzed specialty generic drugs over the study period.
- **Specialty generic drugs help drive parent healthcare conglomerates' operating income:** The top specialty generic drugs accounted for a significant share of the relevant business segments reported by the Big 3 PBMs' parent healthcare conglomerates. Operating income from the Big 3 PBMs' affiliated pharmacies dispensing of the analyzed *specialty generic drugs* accounted for 12 percent of the *aggregated operating income reported by the parent healthcare conglomerates' business segments* that include their PBM and pharmacy businesses in 2021.
- **Plan sponsor and patient drug spending increased significantly:** In 2021, the last year for which the FTC received full-year data for this study, plan sponsors paid \$4.8 billion for specialty generic drugs, while patient cost sharing totaled \$297 million. Between 2017 and 2021 plan sponsors and patient payments both increased at compound annual growth rates of 21% for commercial claims, and 14%-15% for Medicare Part D claims.

**Work expected to continue with new administration**



# Current Issues

---

## Enforcement of HB 226:

- All hands on deck situation
- Division of Insurance [Complaint Process](#)

## Current Legislative Activity

### Cooperative Practice Agreements

- Working to address and resolve Board of Medicine concerns

### Standard of Care Leadership Summit Attendance

### Task Force on Psychedelic Medicines



# Alaska Board of Pharmacy

## Agenda Item #8



## Statutes Discussion



## 2024 STATUTE PROJECT PRIORITIZATION MATRIX

Board: Pharmacy      Date Updated: August 21, 2024

**Part I: Types of Projects:** List the various projects on the board’s radar according to category. Add or edit categories or projects as needed.

	A	B	C	D	E	F
	Statutes	Applications & Fees	Exams	Committees	Enforcement	Other Initiatives
<b>1</b>	AS 08.80.030(b) is amended to read: (19) prohibit, limit, or provide conditions relating to the dispensing of a prescription drug that the United States Food and Drug Administration or the prescription drug's manufacturer has not approved for self-administration to ensure the effectiveness and security of a prescription drug to be administered by infusion or in a clinical setting.	None	None	Next Step – Find legislator support	Incorporate disciplinary guidelines and precedence on the matrix	
<b>2</b>	Statute changes to AS 08.80.337 to allow pharmacists to practice at the top of their clinical ability.	None	None	Next Step – Legislative draft	Incorporate disciplinary guidelines and precedence on the matrix	
<b>3</b>	Remove sections (4) and (6) from AS 08.80.145.	None	Section (6) Removes the Alaska law exam requirement	Next Step – Legislative draft	None	
<b>4</b>						
<b>5</b>						
<b>6</b>						
<b>7</b>						

**Part II: Project Information:** Enter crucial details about the projects to help prioritize the board’s time, effort, and resources.

Project	Authority?	Urgency to Reduce/Prevent Public Harm?	Urgency to Meet Licensee-Related Deadline?	Resources Required?	Priority Ranking and Rationale?	
	Does the board have full control over this issue? If not, is another agency appropriate to lead?	Is this necessary to reduce or prevent harm to the public, such as landowners, wildlife, public land users, etc.	Is a renewal or exam coming up? HR/TAR deadlines? State or federal deadlines? Guiding seasons?	Which board member will take the lead? Is staff needed? Anticipated expenses? Other stakeholders necessary? Public engagement?	Looking at all the information, how should this rank on the timeline of board priorities? <b>Urgent (U):</b> Take immediate steps to complete <b>Scheduled (S):</b> Others more important; can happen as we get to it <b>Postponed (P):</b> Not our issue or not a “must have”	
1A	AS 08.80.030(b) is amended to read: (19) prohibit, limit, or provide conditions relating to the dispensing of a prescription drug that the United States Food and Drug Administration or the prescription drug's manufacturer has not approved for self-administration to ensure the effectiveness and security of a prescription drug to be administered by infusion or in a clinical setting.	Yes				
2A	Statute changes to AS 08.80.337 to allow pharmacists to practice at the top of their clinical ability.	Yes				
3A	Remove section (4) from AS 08.80.145	Yes				
3B	Remove section (6) from AS 08.80.145	Yes				
4A						
5A						

**Part III: Next Steps:** Using the information in Part II, list the *urgent* (U) and *scheduled* (S) projects in order of priority. Include details that support timelines and accountability. Omit postponed projects until they rise to a higher priority and keep track of them above.

Code Assigned	Project	Target Effective Date of Project	Person Responsible for Project Success	Staff Needed to Help Complete Project	Additional Resources, Outreach, Elements	Next Step to Move Forward	Due Date for Next Step
<i>Example:</i>	<i>Regulation XYZ</i>	<i>11-1-23</i>	<i>Board Member A</i>	<i>Board Staff, Regs Specialist, Board Advisor</i>	<i>Additional outreach to large private landowners and native corporations</i>	<i>Board Member A will draft a letter for staff to send to stakeholders and include list of recipients. Announce public forum scheduled for 5-15-23.</i>	<i>Letter to staff by 4-1-23 Sent by 4-5-23</i>
<b>U1</b>							
<b>U2</b>							
<b>U3</b>							
<b>S1</b>							
<b>S2</b>							
<b>S3</b>							

**Part IV: Project Tracker:** Members responsible for the success of the project can use the tracker to organize steps to completion. Duplicate the tracker for every project.

Project:		Code:	Target Effective Date:	
Action needed	Details to complete the action	People involved	Additional resources, concerns	Deadline for action

## 2024 Statute Change Projects and Concepts

### Concepts

- AS 08.80.030(b) is amended to read: (19) prohibit, limit, or provide conditions relating to the dispensing of a prescription drug that the United States Food and Drug Administration or the prescription drug's manufacturer has not approved for self-administration to ensure the effectiveness and security of a prescription drug to be administered by infusion or in a clinical setting.
- Statute changes to AS 08.80.337 to allow pharmacists to practice at the top of their clinical ability.
- Remove sections (4) and (6) from AS 08.80.145

# Alaska Board of Pharmacy

## Agenda Item #9



Adjourn for Lunch

# Alaska Board of Pharmacy

## Agenda Item #10



Roll Call/Call to Order

## Alaska Board of Pharmacy Roster

Board Member Name	Initial Appointment	Reappointed	Term End
Ashley Schaber, PharmD	07/01/2021	03/01/2024	03/01/2028
Sylvain Nouvion, PharmD., Ph.D.	05/31/2023		03/01/2027
James Henderson, RPh	03/01/2017	03/01/2021	03/01/2025
Ramsey Bell, RPh	03/01/2022		03/01/2026
Carla Hebert, RPh	01/05/2023	03/01/2024	03/01/2028
Sara Rasmussen, Public Member	03/01/2023		03/01/2027
Dylan Sanders, Pharmacy Technician	10/28/2024		03/01/2028

Name	Position	Committee Membership/Additional Duties
Ashley Schaber	Chair	Statutes and Regulations
James Henderson		Statutes and Regulations, Compounding
Ramsey Bell		Well-Being
Carla Hebert	Vice Chair	Compounding, Well-Being
Sara Rasmussen		Statutes and Regulations, Controlled Substances Advisory Committee Chair
Sylvain Nouvion	Secretary	Statutes and Regulations
Dylan Sanders		

# Alaska Board of Pharmacy

## Agenda Item #11



## Regulations Discussion



## 2024 REGULATION PROJECT PRIORITIZATION MATRIX

Board: Pharmacy      Date Updated: August 21, 2024

**Part I: Types of Projects:** List the various projects on the board’s radar according to category. Add or edit categories or projects as needed.

	A	B	C	D	E	F
	Regulation Change	Applications & Fees	Exams	Committees	Enforcement	Other Initiatives
<b>1</b>	Align statutes and regulations with Pharmacist Intern vs Pharmacy Intern language. “Pharmacy Intern” is used 5 times in statute and 11 times in regulation. “Pharmacist Intern” is used 0 times in statute and 47 times in regulation.	None	None	Next Step - Statutes and Regulations committee to craft language	None	
<b>2</b>	Creating regulations requiring national background checks for pharmacists and pharmacy technicians.	None	None	Next Step - Statutes and Regulations committee to craft language	Review disciplinary guidelines and precedence on the matrix for non-disclosures	
<b>3</b>	Broadening the options in regulations for continuing education.	None	None	Next Step - Statutes and Regulations committee to craft language	None	
<b>4</b>	Amending the language in regulation requiring reinstatement for pharmacist and pharmacy technician language in 12 AAC 52.310	Fee change in central statute/regs will need to occur when the regulation changes goes in to effect.	None	Next Step - Statutes and Regulations committee to craft language	None	
<b>5</b>	Removing the requirements for notarization for all application types and associated documents.	None	None	Next Step - Statutes and Regulations committee to craft language	None	
<b>6</b>	Streamline regulatory language to incorporate the standard of care concept.					
<b>7</b>						

**Part II: Project Information:** Enter crucial details about the projects to help prioritize the board’s time, effort, and resources.

Project	Authority?	Urgency to Reduce/Prevent Public Harm?	Urgency to Meet Licensee-Related Deadline?	Resources Required?	Priority Ranking and Rationale?	
	Does the board have full control over this issue? If not, is another agency appropriate to lead?	Is this necessary to reduce or prevent harm to the public, such as landowners, wildlife, public land users, etc.	Is a renewal or exam coming up? HR/TAR deadlines? State or federal deadlines? Guiding seasons?	Which board member will take the lead? Is staff needed? Anticipated expenses? Other stakeholders necessary? Public engagement?	Looking at all the information, how should this rank on the timeline of board priorities? <b>Urgent (U):</b> Take immediate steps to complete <b>Scheduled (S):</b> Others more important; can happen as we get to it <b>Postponed (P):</b> Not our issue or not a “must have”	
1A	Align statutes and regulations with Pharmacist Intern vs Pharmacy Intern language. “Pharmacy Intern” is used 5 times in statute and 11 times in regulation. “Pharmacist Intern” is used 0 times in statute and 47 times in regulation.	Yes				
2A	Creating regulations requiring national background checks for pharmacists and pharmacy technicians.	Yes				
3A	Broadening the options in regulations for continuing education.	Yes				
4A	Amending the language in regulation requiring reinstatement for pharmacist and pharmacy technician language in 12 AAC 52.310	Yes				
5A	Removing the requirements for notarization for all application types and associated documents.	Yes				
6A						

**Part III: Next Steps:** Using the information in Part II, list the *urgent* (U) and *scheduled* (S) projects in order of priority. Include details that support timelines and accountability. Omit postponed projects until they rise to a higher priority and keep track of them above.

Code Assigned	Project	Target Effective Date of Project	Person Responsible for Project Success	Staff Needed to Help Complete Project	Additional Resources, Outreach, Elements	Next Step to Move Forward	Due Date for Next Step
<i>Example:</i>	<i>Regulation XYZ</i>	<i>11-1-23</i>	<i>Board Member A</i>	<i>Board Staff, Regs Specialist, Board Advisor</i>	<i>Additional outreach to large private landowners and native corporations</i>	<i>Board Member A will draft a letter for staff to send to stakeholders and include list of recipients. Announce public forum scheduled for 5-15-23.</i>	<i>Letter to staff by 4-1-23 Sent by 4-5-23</i>
<b>U1</b>							
<b>U2</b>							
<b>U3</b>							
<b>S1</b>							
<b>S2</b>							
<b>S3</b>							

**Part IV: Project Tracker:** Members responsible for the success of the project can use the tracker to organize steps to completion. Duplicate the tracker for every project.

Project:		Code:	Target Effective Date:	
Action needed	Details to complete the action	People involved	Additional resources, concerns	Deadline for action

Regulations Changes Approved November 14, 2024

It was resolved to repeal 12 AAC 52.100(a)(4).

It was resolved to repeal 12 AAC 52.100(a)(6).

12 AAC 52.020. PHARMACY LICENSE.

(f) A pharmacy that has changed its name, ownership, or physical address shall notify the board in writing not later than 30 days after the change. A notification of a change [of physical address] must include **a current and active license from the home jurisdiction showing the change in name, ownership, or physical address and** an attestation that a new self-inspection will be completed not later than 30 days after the start of business in the new location.

12 AAC 52.610. WHOLESALE DRUG DISTRIBUTOR LICENSE.

(c) A wholesale drug distributor that has changed its name, physical address, or ownership must notify the board in writing not later than 30 days after the change. A notification of a change [of physical address] must include **a current and active license from the home jurisdiction showing the change in name, ownership, or physical address and** an attestation that a new self-inspection will be completed not later than 30 days after the start of business.

12 AAC 52.696. OUTSOURCING FACILITIES.

(c) An outsourcing facility that has changed its name, physical address, or ownership must notify the board in writing not later than 30 days after the change. The notification must include **a current and active license from the home jurisdiction showing the change in name, ownership, or physical address and** an attestation that a new self-inspection will be completed not later than 30 days after the start of business.

12 AAC 52.697. THIRD-PARTY LOGISTICS PROVIDERS.

(c) A third-party logistics provider that has changed its name, physical address, or ownership must notify the board in writing not later than 30 days after the change. The notification must include **a current and active license from the home jurisdiction showing the change in name, ownership, or physical address and** an attestation that a new self-inspection will be completed not later than 30 days after the start of business.

12 AAC 52.698. MANUFACTURER LICENSE.

(d) A manufacturer that has changed its name, physical address, or ownership must notify the board in writing not later than 30 days after the change. The notification of a change [of physical address] must include **a current and active license from the home jurisdiction showing the change in name, ownership, or physical address and** an attestation that a new self-inspection will be completed not later than 30 days after the start of business.

## Background check Issues:

It is recommended that background check language be added to the specific application section of Pharmacist and Pharmacy Technician similar to the following but not in its own section:

### **12 AAC 79.130. CRIMINAL JUSTICE INFORMATION.**

(a) An applicant for licensure under 12 AAC 79.100, 12 AAC 79.110, or 12 AAC 79.120 must submit with the application the applicant's fingerprints and other information required by the Department of Public Safety to obtain state and national criminal justice information under AS 12.62 and AS 12.64.

(b) The board will submit the fingerprints received under this section to the Department of Public Safety and request the Department of Public Safety to

(1) submit the fingerprints to the Federal Bureau of Investigation for a report on national criminal justice information;

(2) perform a check for state criminal justice information; and

(3) report to the board the results of the criminal justice information checks under (1) and (2) of this subsection.

(c) The request under (b) of this section for a criminal justice information report does not delay administrative processing of the applicant's license application. An application will not be considered complete until the criminal justice information required in (a) of this section is received by the board. If criminal justice information that raises questions about an applicant's qualifications for licensure is received after a license has been issued to the applicant, the department and the board will take action under AS 08.61 and AS 44.62 as appropriate.

### **12 AAC 79.120. APPLICATION FOR TRANSITIONAL LICENSE.**

(a) The board will issue a license under this section to an applicant who applies for licensure before July 1, 2017, and who meets the requirements of AS 08.61.030(1), (2), (4) – (6), and (9) and this section.

(b) An applicant for licensure under this section must submit

(1) a completed application, on a form provided by the department; the completed application must include

(A) the personal identification information requested on the form;

(B) information related to the grounds of disciplinary sanctions under AS 08.61.060;

(C) the applicant's fingerprint information described in 12 AAC 79.130; and

(D) the application fee, fingerprint processing fee, and license fee specified in 12 AAC 02.396;

## **Other considerations:**

AS 12.62.400(a):

"To obtain a national criminal history record check for determining a person's qualifications for a license, permit, registration, employment, or position, a person shall submit the person's fingerprints to the department with the fee established by AS 12.62.160. The department may

submit the fingerprints to the Federal Bureau of Investigation to obtain a national criminal history record check of the person for the purpose of evaluating a person's qualifications for one of the listed practices or professions listed in the numbered paragraphs that follow.

This means the board can only request background checks on Pharmacist and Pharmacy Technician applicants and those applicants must submit a fingerprint card to the Department, they cannot complete the process themselves.

- 1. Statutory authority must exist for boards to require criminal history background checks as part of the licensing process.** Only [certain licensing programs](#) may obtain fingerprint checks (per their statutes).
- 2. Any regulations regarding background checks should be clear and implementable.** Processes and standards outside Alaska are unknown.
- 3. The current regulations for jurisdictional background checks (assuming they are valid) are limited in value/costly/lead to denials.** Alaska authorizes a [“name-based” check](#) that may not reveal correct, thorough, or relevant information. A board that cannot rely on the document provided is obliged to deny the license, creating an appeal process that is time consuming, expensive, and ultimately a liability to the board.
- 4. The current regulations for jurisdictional background checks may not be admissible, usable, or even available.** I am using the term “jurisdictional” because applicants from locations outside Alaska are also expected to provide this documentation. However, the citations provided in the attachment refer to a “state” rather than a jurisdiction. Does a “state” standard apply to territories, or even other countries? If so, how do we assess the validity of the document if it comes directly from the licensee and can't be verified? Several boards with state background check authority cite AS 12.62; however, these references do not provide any authority to the Alaska board to seek primary source verification. What if the document isn't in English? What if a “Class B Felony” has a different meaning in another state or country than Alaska? What does licensing staff so when the document from another state has a “Not for use in licensure” stamp across its face—which has been a problem for CBPL programs for years. What if an applicant is unable to obtain a background check because their country doesn't provide them or another legitimate administrative reason—such as a global pandemic, war, or lack of staffing? These barriers increase the temptation to use easily available design software to create false documents or alter official documents. Another concern is how an applicant is expected to provide an Alaska report if they have never set foot in this state. In the day age of “telepractice,” is it reasonable or even feasible to require an Alaska background check if someone has no intention of living in or visiting Alaska?
- 5. Jurisdictional background checks will exponentially increase the confusion and workload of the applicant, board, and staff.** In addition to the higher administrative standards for screening, handling, and storing criminal history record information (CHRI), the complications mentioned above will frustrate applicants, resulting in increased correspondence about compliance. Staff will have to work through each of the

scenarios mentioned in #4, then pass those situations along to the board for review. Does licensing staff have time to review what an Assault 4 conviction in Missouri translates to in Alaska? Does licensing staff have the capacity to translate a document provided in Russian? These are not scenarios that lead to a streamlined, efficient, right-touch regulatory process. A board that cannot rely on the document provided is obliged to deny the license, creating an appeal process that is time consuming, expensive, and ultimately a liability to the board. Creating an impossible process or improperly denying a license because the licensing examiner could not translate the language or criminal history meanings to the board will likely lead to a recommendation to eliminate this regulation altogether.

➤ Questions arise:

- ❖ How to assess the validity of a document that comes directly from the licensee and can't be verified?
- ❖ What if the document isn't in English?
- ❖ What if a "Class B Felony" has a different meaning in another state or country than Alaska?
- ❖ What does licensing staff do when the document from another state has a "Not for use in licensure" stamp across its face?
- ❖ What if an applicant is unable to obtain a background check because their country doesn't provide them or another legitimate administrative reason?
- ❖ How is an applicant expected to provide an Alaska report if they have never set foot in this state? Is it reasonable or even feasible to require an Alaska background check if someone has no intention of living in or visiting Alaska?
- ❖ Does licensing staff have time to review what an Assault 4 conviction in Missouri translates to in Alaska?
- ❖ Does licensing staff have the capacity to translate a document provided in Russian?

# Alaska Board of Pharmacy

## Agenda Item #12



Public Comment Period



# Alaska Board of Pharmacy

## Agenda Item #13



## Board Business

**From:** [National Association of Boards of Pharmacy Foundation@](#)  
**To:** [Bowles, Michael P \(CED\)](#)  
**Subject:** Public Comment Period is Open for Revised JCPP Pharmacists' Patient Care Process  
**Date:** Friday, January 31, 2025 11:14:55 AM

You don't often get email from nabpfoundationresearch@nabp.pharmacy. [Learn why this is important](#)

**CAUTION:** This email originated from outside the State of Alaska mail system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

## Share your Opinions



### **Share Your Opinions: Open Public Comment Period for the Revised JCPP Pharmacists' Patient Care Process**

The Pharmacists' Patient Care Process (PPCP) is the foundation for the essential care that pharmacists provide to patients on a daily

basis. 15 national pharmacy organizations have collaborated through the Joint Commission of Pharmacy Practitioners (JCPP) to revise the 2014 PPCP to reflect contemporary pharmacy practice today and into the future. These organizations are now seeking feedback on the revised draft PPCP from pharmacists across the profession to ensure that it is reflective of diverse pharmacy practice settings and the care being delivered.

Your voice is important! Please contribute your feedback by accessing the draft revised PPCP and a feedback survey.

[Share My Feedback](#)

The estimated time to review the draft revised PPCP is 10 minutes, and the feedback survey is estimated to take up to 20 minutes to complete. The feedback survey does not collect information that could identify an individual respondent unless the individual chooses to provide a name and email at the end, but it does collect data that identifies the organization from whose invitation the individual responded.

The public comment period will be open until Friday, February 28 at 5 PM PT.



The National Association of Boards of Pharmacy Foundation<sup>®</sup> (NABPF<sup>®</sup>) is an Illinois not-for-profit corporation formed to support the Association's research and developmental projects and educational programs.

[Unsubscribe](#)

This message was sent to [michael.bowles@alaska.gov](mailto:michael.bowles@alaska.gov) from  
[NABPFoundationResearch@nabp.pharmacy](mailto:NABPFoundationResearch@nabp.pharmacy)

National Association of Boards of Pharmacy Foundation<sup>®</sup>  
NABP Foundation  
1600 Feehanville Dr  
Mount Prospect, IL 60056



THE STATE  
of **ALASKA**  
GOVERNOR MIKE DUNLEAVY

Department of Commerce, Community, &  
Economic Development

Corporations, Business, & Professional Licensing  
Board of Pharmacy

P.O. Box 110806  
Juneau, Alaska 99811-0806  
Main: 907.465.2550  
Fax: 907.465.2974

January 3, 2025

Emily Ricci  
Deputy Commissioner  
Alaska State Department of Health  
350 Main Street, Room 304  
Juneau, Alaska 99811  
Emily.Ricci@alaska.gov

Re: 2024 Medicaid Cost of Dispensing (COD) Survey; Medicaid Dispensing Fees

Dear Deputy Commissioner Ricci,

The Board of Pharmacy ("board") is writing to express concerns with the proposed decrease in dispensing fees as the result of the 2024 Cost of Dispensing (COD) survey. The board endeavors to promote, preserve, and protect the public health, safety, and welfare by and through the effective control and regulation of the practice of pharmacy. Over the last few years, the board has received many comments from Alaskan pharmacists, technicians, members of the public, and organizations about various practices limiting access to Alaskan pharmacies and compromising the safety of medications received in the state. Subsequently, the board has supported multiple state and federal initiatives to maintain and grow access to pharmacies in Alaska.

A decrease in the Medicaid dispensing fees for Alaska's pharmacies will negatively impact an already fragile pharmacy infrastructure in Alaska. We respectfully request that you consider this negative impact to care access when finalizing the dispensing fee rates for pharmacies in the state. Maintaining access to local pharmacies is crucial to ensure public health and access to care in Alaska. The current interim rates should be maintained until further assessment can be completed.

Thank you,

A handwritten signature in cursive script that reads "Ashley Schaber".

Ashley Schaber, PharmD, MBA, BCPS  
Chair, Alaska Board of Pharmacy

**From:** [Eric Bauer](#)  
**To:** [Board of Pharmacy \(CED sponsored\)](#)  
**Cc:** [CAPS\\_RegulatoryAffairs.BBMUS\\_Service](#)  
**Subject:** Adverse Drug Event (ICSR ID 2168205)  
**Date:** Tuesday, January 7, 2025 6:40:23 AM  
**Attachments:** [ICSR 2168205 CAPS Phoenix.pdf](#)  
[State Notification Alaska 1.3.20251.pdf](#)

---

**CAUTION:** This email originated from outside the State of Alaska mail system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

To: Alaska Board of Pharmacy/ BoardofPharmacy@alaska.gov

Re: FDA report of Adverse Drug Event (ICSR ID 2168205)/ Outsourcing Reg# 169886

To Whom it May Concern:

Per your state requirements, we are providing you with a copy of an Adverse Drug Event that we reported to the FDA on January 3, 2025.

Best Regards,

**Eric Bauer, RPh, BCSCP**

Senior Director of Policy and External Affairs  
Central Admixture Pharmacy Services  
862-216-9202 | [Eric.Bauer@CAPSPharmacy.com](mailto:Eric.Bauer@CAPSPharmacy.com)

---

The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of the company of the sender of this e-mail. Unauthorized use, disclosure, or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail and destroy this communication and all copies thereof, including all attachments.



Central Admixture Pharmacy Services, Inc.  
2200 South 43<sup>rd</sup> Avenue  
Phoenix, AZ 85043

January 3, 2025

Alaska Board of Pharmacy  
BoardofPharmacy@alaska.gov

Re: FDA report of Adverse Drug Event (ICSR ID 2168205)

To Whom it May Concern:

Per your state requirements, we are providing you with a copy of an Adverse Drug Event that we reported to the FDA on January 3, 2025.

Best Regards,

Eric Bauer

Senior Director of Policy and External Affairs  
Central Admixture Pharmacy Services, Inc.

# REPORT INFORMATION

## Report Profile

**Report Version** FPSR.FDA.SPHR.M.V4

**Report Category** Marketed Human Drug, Therapeutic Biologics, and Cosmetic Report V4

**Submitted** 2025-01-02 09:50:35 EST

**FDA ICSR ID** 2168205

**Submitted by** eric.bauer@capspharmacy.com

## Report Identifying Information

**Enter a title to help you identify this report** CAPS Phoenix-Essentia Health St Marys Medical Cent

**Combination Product Report** No

**Type of report** Expedited (15 day)

**Report Expedited Selection** Yes

**Have you initially reported on this case using a paper form?** No

**Safety report ID (MCN)** US-Central Admixture Pharmacy Services, Inc. - Phoenix-2168205

**Is the World Wide Unique Number the same as the Safety report ID?** Yes

**World Wide Unique Number** US-Central Admixture Pharmacy Services, Inc. - Phoenix-2168205

**Date initial report received** 12/20/2024

**Date information received in most recent report** 12/20/2024

**Date information received in this report** 12/20/2024

**Country where the event occurred** UNITED STATES

**Report source** Spontaneous

# SPHR E2B R3 Message Sender

**Sender Type** 1  
**Organization** Central Admixture Pharmacy Services, Inc. - Phoenix  
**Department** NA  
**Title** Mr.  
**First Name** Eric  
**Middle Name** W  
**Last Name** Bauer  
**Street Address** 2200 South 43rd Avenue  
**City** Phoenix  
**State / Province** AZ  
**ZIP / Postal Code** 85043  
**Country** US  
**Telephone** 9999999999  
**Fax** 12015419816  
**E-mail** eric.bauer@capspharmacy.com

---

## Contact Information - Reporter(s)

**Is this the primary reporter?** Yes  
**Title** Ms.  
**First name** Lahana  
**Middle name** <blank>  
**Last name** Koivisto  
**Qualification** Other health professional  
**Organization name** Essentia Health St Marys Medical Center  
**Department** Pharmacy  
**Country** UNITED STATES  
**Street address** <blank>  
**City** Duluth  
**State** Minnesota  
**Zip/Postal code** 55805  
**Email Address** lashana.Koivisto@essentiahealth.org



# Patient Information

**Patient identifier** <blank>  
**Date of birth** <blank>  
**Age at the time of the event** <blank>  
**Select unit of measure** <blank>  
**Patient sex** Male  
**Patient weight** 2.43  
**Select unit of measure** kilograms (kgs)  
**Weight (kg)** 2.43  
**Ethnicity** Unknown

---

# Race

**Race** Unknown

---

# Relevant Medical History and Concurrent Conditions

**Do you have any relevant medical history data information to report?** No

---

# Relevant Medical History and Concurrent Conditions Details

---

# Additional Medical History or Concurrent Conditions Information

**E2BR3 Additional medical history** None

---

# Results of Tests and Procedures

**Do you have any relevant tests/laboratory data information to report?** No

---

# Results of Tests and Procedures Details

---

## Adverse Event Details

**Verbatim term** Extravasation occurred on 12/15/2024 during IV infusion of compounded TPN Starter Bag to a male new infant patient, weighing 2.43 kg.

**Adverse event** Administration site extravasation

**Start date** 12/15/2024

**Adverse event outcome** Unknown

**Country where \*this\* event occurred** UNITED STATES

---

## Event Outcome

**Death** <blank>

**Life threatening** <blank>

**Hospitalization - initial or prolonged** <blank>

**Disability/incapacity** <blank>

**Congenital anomaly/birth defect** <blank>

**Other serious, important medical events** Yes

**Required intervention to prevent permanent impairment or damage** <blank>

---

## Adverse Event Description

**Death date (in case of death)** <blank>

**Was Autopsy Done?** <blank>

**Please describe the adverse event or problem**

Extravasation occurred on 12/15/2024 during IV infusion of compounded TPN Starter Bag ("Trophanine 4%/ Dextrose 10% w/ Ca Gluc & Heparin 250mL; NDC 0422-1; lot#36-271189) to a male infant patient, weighing 2.43 kg. The site of infusion was in the patient's right hand, at a rate of 70ml/kg/d. The extravasation was discovered at approximately 55 minutes after the start of the infusion. Actions taken: the PIV [Peripheral IV] was removed, hyaluronidase (150 units given) was administered.

---

## Primary Suspect Product Information

**Product Role (Primary Suspect Product)** Suspect

Please describe <blank>

Drug authorization number (Enter COMP99 for compounding product) COMP99

Name of holder/applicant Central Admixture Pharmacy Services, Inc. - Phoenix

Action taken with drug Drug withdrawn

NDC number or Unique ID 72196-0422-1

Additional Information on Drug (free text) NDC: 72196-0422-1 - 36-271189/ January 4, 2025

## Primary Suspect Product Use Details

Lot number/Expiration date 36-271189/ January 4, 2025

Therapy/Usage start date 12/15/2024

Therapy/Usage end date 12/15/2024

Duration of Product Administration 55

Select unit of measure Minute

Dose 70

Select unit of measure Millilitre Per Kilogram

Frequency of the product used 1

Select unit of measure Day

Dosage form Injection

Route of administration Intravenous

Did the reaction recur on readministration? <blank>

## Primary Suspect Product Active Ingredient Details

Active ingredient name AMINO ACIDS\CALCIUM GLUCONATE MONOHYDRATE\DEXTROSE MONOHYDRATE\HEPARIN SODIUM

## Primary Suspect Product Indication for Use Details

Diagnosis for use (Indication) Parenteral nutrition

## Device Component Information

---

## Other Product Information

---

## HL7 Batch Information

---

## HL7 Batch Control Information

---

## HL7 Message Information

---

## HL7 Message Control Information

Safety Report Id (SPHR) US-Central Admixture Pharmacy Services, Inc. - Phoenix-2168205

---

## Attachments

Are Additional Documents Available? False

---

## Attached Files

None



# ALASKA BOARD OF PHARMACY

## 2024 STRATEGIC PLAN

The Alaska Board of Pharmacy endeavors to promote, preserve, and protect the public health, safety, and welfare by and through the effective control and regulation of the practice of pharmacy.

### GUIDING PRINCIPLES

### GOALS

### STRATEGIES



#### COMMUNICATION

1. Engage in effective communication and promote transparency of public information.

- 1.1 Improve customer service by providing timely and informative updates to applicants and licensees.
- 1.2 Maximize communication channels through the Board of Pharmacy website and List Service.
- 1.3 Maintain accuracy of website content and ensure accessibility of up-to-date resources



#### ADMINISTRATION

2. Adhere to and strive for improved organizational efficiencies without compromising quality of record keeping.

- 2.1 Avoid delays in application processing by maintaining adequate staffing and exploring flexible retention strategies.
- 2.2 Maintain a proactive approach to licensing by consulting historical knowledge, researching national trends, and encouraging innovation in the planning process.
- 2.3 Automate initial licensure through online applications.
- 2.4 Exercise fiscal discipline through effective budget management.
- 2.5 Embrace innovation by exploring integration and/or delegation opportunities to support core administration functions.



#### LICENSURE

3. Ensure competency and qualifications prior to licensure and renewal.

- 3.1 Adhere to established licensing standards by reviewing education, experience, and examination requirements.
- 3.2 Take a proactive approach to application and form revision subsequent to regulation changes.
- 3.3 Ensure a 14 day or less processing time for licensee applications, and a 30 day or less licensing time for facility applications.



#### REGULATION & ENFORCEMENT

4. Grow the economy while promoting community health and safety.

- 4.1 Routinely review effectiveness of regulations that reduce barriers to licensure without compromising patient health and safety.
- 4.2 Combat the opioid crisis by effective administration of the state's Prescription Drug Monitoring Program (PDMP), including collaboration with providers and key stakeholders.
- 4.3 Advocate for legislation addressing access to pharmacies as the pharmacy profession evolves and new opportunities for improved patient safety arise.
- 4.4 Anticipate changes to the Drug Supply Chain Security Act and respond proactively. Address changes to compounding.

**For more information, please visit the following resources:**

Board of Pharmacy Homepage: [pharmacy.alaska.gov](http://pharmacy.alaska.gov)  
 Prescription Drug Monitoring Program (PDMP): [pdmp.alaska.gov](http://pdmp.alaska.gov)

Email: [boardofpharmacy@alaska.gov](mailto:boardofpharmacy@alaska.gov)  
 Phone: 907-465-1073

# PRIORITIZATION MATRIX

Board: *Pharmacy*

Date Updated:

**Part I: Types of Projects:** List the various projects on the board’s radar according to category. Add or edit categories or projects as needed.

	A	B	C	D	E	F
	Regulations	Applications & Fees	Exams	Committees	Enforcement	Other Initiatives
1						
2						
3						
4						
5						
6						
7						
8						
9						
10						

**Part II: Project Information:** Enter crucial details about the projects to help prioritize the board’s time, effort, and resources.

	Project	Authority?	Urgency to Reduce/Prevent Public Harm?	Urgency to Meet Licensee-Related Deadline?	Resources Required?	Priority Ranking and Rationale?
		Does the board have full control over this issue? If not, is another agency appropriate to lead?	Is this necessary to reduce or prevent harm to the public?	Is a renewal or exam coming up? State or federal deadlines? Industry-related seasons?	Which board member will take the lead? Is staff needed? Anticipated expenses? Other stakeholders necessary? Public engagement?	Looking at all the information, how should this rank on the timeline of board priorities? <b>Urgent (U):</b> Take immediate steps to complete <b>Scheduled (S):</b> Others more important; can happen as we get to it <b>Postponed (P):</b> Not our issue or not a “must have”
1A						
2A						

1B						
2B						
1C						
2C						
1D						
1E						
1F						

**Part III: Next Steps:** Using the information in Part II, list the *urgent* (U) and *scheduled* (S) projects in order of priority. Include details that support timelines and accountability. Omit postponed projects until they rise to a higher priority and keep track of them above.

Code Assigned	Project	Target Effective Date of Project	Person Responsible for Project Success	Staff Needed to Help Complete Project	Additional Resources, Outreach, Elements	Next Step to Move Forward	Due Date for Next Step
<i>Example:</i>	<i>Regulation XYZ</i>	<i>11-1-23</i>	<i>Board Member A</i>	<i>Board Staff, Regs Specialist, Board Advisor</i>	<i>Additional outreach to large private landowners and native corporations</i>	<i>Board Member A will draft a letter for staff to send to stakeholders and include list of recipients. Announce public forum scheduled for 5-15-23.</i>	<i>Letter to staff by 4-1-23 Sent by 4-5-23</i>
U1							
U2							
U3							
S1							
S2							
S3							

**Part IV: Project Tracker:** Members responsible for the success of the project can use the tracker to organize steps to completion. Duplicate the tracker for every project.

<b>Project:</b>		<b>Code:</b>	<b>Target Effective Date:</b>	
Action needed	Details to complete the action	People involved	Additional resources, concerns	Deadline for action




Department of Commerce, Community  
and Economic Development

---

Division of Corporations, Business  
and Professional Licensing

## **Alaska Board of Pharmacy**

### **Annual Report**

Fiscal Year 2024



Department of Commerce, Community and Economic Development  
Division of Corporations, Business and Professional Licensing

P.O. Box 110806  
Juneau, Alaska 99811-0806  
Email: [License@Alaska.Gov](mailto:License@Alaska.Gov)

*This report is required under Alaska Statute 08.01.070(10).*

**Alaska Board of Pharmacy  
FY 2024 Annual Report**

**Table of Contents**

Board Membership

**Page 1**

Accomplishments

**Page 2**

Activities

**Page 4**

Needs

**Page 5**

Alaska Board of Pharmacy  
FY 2024 Annual Report

**Board Membership (as of the Date This Report was Approved)**

**Date of Final Board Approval:** 5/31/2024

Board Members:

Ashley Schaber, Pharmacist (Chairperson)

James Henderson, Pharmacist

Carla Hebert, Pharmacist

Ramsey Bell, Pharmacist

Sylvain Nouvion, Pharmacist

Cynthia Maxwell, Pharmacy Technician

Sara Rasmussen, Public Member

**Alaska Board of Pharmacy  
FY 2024 Annual Report**

**Accomplishments**

The Board of Pharmacy "the board" submits this report highlighting its endeavors to promote the welfare and safety of the public through the effective regulation of the pharmacy profession and pharmaceutical supply chain in Alaska for FY24. This year, the Board of Pharmacy: sent email notification to licensees of meetings, notified licensees via listserve of licensing process changes and updated statutes/regulations, continued work on statute and regulation changes with a barrier-reduction regulatory framework to support pharmacy services and the growth of the Alaskan economy, with many regulatory changes effective in January and May 2024. Below is a summary of the Board's legislative, regulatory, and licensing accomplishments.

Legislative Accomplishments:

- Relevant legislation in FY24 includes House Bill 112 (Profession of Pharmacy), an effort led by the Board of Pharmacy with support from and collaboration with the Alaska Pharmacists Association. HB 112 sponsored by Representative Justin Ruffridge, and signed into law by the Governor in July 2023, streamlines the licensure process while improving public safety including the statutory authority to require background checks; aligns pharmacy statutes with other Alaska boards and other states' statutes by replacing one of the two public member seats with a pharmacy technician seat, recognizing retired pharmacists, and allowing flexibility for a pharmacist to serve in the Board's executive administrator role; increases access to epinephrine auto-injectors, medication delivery devices for anaphylaxis emergencies; and ensures the Board's powers and duties support the federal Drug Supply Chain and Security Act (DSCSA) to ensure Alaskans receive safe medications.
- The board's other major legislative priority is addressing Pharmacy Benefits Manager practices impacting access to care for Alaskans. House Bill 226 (Pharmacies/Pharmacists/Pharmacy Benefits Managers), sponsored by Representative Jesse Sumner, a collaborative effort supported by the Alaska Pharmacy Association, the Board of Pharmacy, and multiple other patient care and healthcare organizations, passed the Legislature in May 2024 and is awaiting the Governor's signature. The changes in this bill will begin to address Pharmacy Benefits Managers' practices including white-bagging and brown-bagging and spread-pricing, which have been identified as having a negative impact on patient care, public health infrastructure, and pharmacy access in Alaska. The board has received feedback about these practices in the form of public comment and industry updates over the past few years and appreciated the opportunity to support and advocate for HB 226.
- Recognizing the need for efficient license pathways and processes, the Board of Pharmacy supported SB 83 (Professional Licensing; Temp Permits) and its companion bill HB 85 in the 33<sup>rd</sup> Legislative Session. The board acknowledged that these bills expand the temporary license period the Board currently has in place from 90 days to 180 days and provides an efficient pathway for pharmacists and pharmacy technicians to not only work under a temporary license but also to obtain permanent licensure in Alaska.
- The Board supported and advocated for pharmacist representation on the Mental Health/Psychadelic Medication task force proposed in HB228/SB166. This advocacy resulted in an amendment to the bill adding a pharmacist selected by the Alaska Pharmacy Association Board of Directors to the task force.

**Alaska Board of Pharmacy  
FY 2024 Annual Report**

**Accomplishments**

**Regulation Accomplishments:**

- Effective January 2024: The Board of Pharmacy implemented multiple changes in title 12, Chapter 52 of the Alaska Administrative Code to update and remove various regulations to align with changes in HB 112 and HB 56 while at the same time meeting Governor Dunleavy’s expectation of “right touch” regulation throughout the state. These include several areas of licensing and operational efficiency as well as practice advancement, including: removing the pharmacy regulatory barrier for pharmacists to prescribe Medication Assisted Therapy for opioid use disorder under collaborative practice agreement with a physician, amending the requirements of pharmacy technicians to lower the age to become licensed from 18 to 16 years of age if the applicant is in a supervised high school, college, or apprenticeship training program, and the adding of the standard of care model for pharmacy.
- Effective May 19, 2024: The Board of Pharmacy through regulation change removed the requirement for pharmacist applicants to take the multi-state jurisprudence exam administered by the National Association of Boards of Pharmacy (NABP); removed the requirement for pharmacists working at tribal health programs to submit an exemption to practice in Alaska with a pharmacist license from another jurisdiction; and added language to regulation which aligns with the standard of practice model addressing unexpected closures of pharmacies and continuity of patient care.
- Pending notice and review of public comment, the Board of Pharmacy has proposed a new regulation project to allow for non-punitive addiction treatment for licensees who self-disclose opioid use or alcohol use disorder and seek assistance in this area; define pharmacy and facility ownership and changes in ownership; allow pharmacy technicians to practice at the top of their training and ability; clarify pharmacist registration requirements for the PDMP; update sterile compounding regulatory guidelines to a standard of practice model; and remove board approval for collaborative practice agreements between pharmacists and practitioners.

**Licensing Accomplishments:**

- The Board of Pharmacy advocated for and supported online initial license applications. To date, the initial license applications for technicians and pharmacists are available online. Pharmacy intern and initial facility license applications will follow. These changes have significantly improved license processing turnaround times for technicians and pharmacists.

**Alaska Board of Pharmacy  
FY 2024 Annual Report**

**Activities**

FY24 Board of Pharmacy Meetings:

- August 3 (Statute and Regulation Committee Meeting)
- August 10 (Quarterly Meeting, including Investigative, Division Licensing, Budget, and PDMP updates)
- November 16 (Quarterly Meeting, including Investigative, Division Licensing, Budget, and PDMP updates)
- December 7 (Special Meeting covering regulations and guest speakers on the Just Culture concept)
- February 15 (Quarterly Meeting, including Investigative, Division Licensing, Budget, and PDMP updates)
- April 11 (Quarterly Meeting, including Investigative, Division Licensing, Budget, and PDMP updates)

FY24 Professional Meetings Attended:

- October NABP District 6,7,8 Meeting: Collaboration with the American Association of Colleges of Pharmacy (AACP) and State Pharmacy Assn Leaders; 1 Board Member, Executive Administrator
- November Online FDA 2023 Intergovernmental Working Meeting on Drug Compounding: 1 Board Member, Executive Administrator
- February AKPhA Annual Conference: 2 Board Members, Executive Administrator
- April Rx and Illicit Drug Summit: 1 Board Member, PDMP Manager, Executive Administrator
- May NABP Annual Meeting: 1 Board Member, Executive Administrator

New/Continued Initiatives:

- Partnership with AKPhA and UAA/Idaho State University College of Pharmacy for regular updates on initiatives during Board quarterly meetings
- Exploring offering continuing education (CE) for portions of Board meetings
- Publication and distribution of a regular newsletter for all licensees through a partnership with NABP.
- Just Culture- the Board of Pharmacy is exploring how this concept can be applied as a regulatory board.
- Updates to the State Medical Board (February 2024; planned regularly)
- “Implementing Solutions: Building a Sustainable, Healthy Pharmacy Workforce and Workplace”: the Board performed an assessment and gap analysis of the actionable NABP/Boards of Pharmacy solutions recommended from the American Pharmacists Association/American Society of Healthsystem Pharmacy/NABP June 2023 Summit. The Board is utilizing this assessment to pursue statutory, regulatory, and operational changes to support a sustainable, healthy pharmacy workforce and workplace.

**Alaska Board of Pharmacy  
FY 2024 Annual Report**

**Needs**

- Legislative Priorities
  - Addressing Pharmacy Benefits Managers practices impacting safety, access, and transparency for Alaskan patients and pharmacies. The Board plans continued collaboration on state and federal efforts to address these practices during FY25.
  - Streamlining Licensure Process for Pharmacists
    - The Board implemented regulation changes repealing the law exam requirement for pharmacists applying for licensure by examination and replace it with a legally binding attestation. These regulation changes went into effect May 19, 2024.
    - Statute change is required to remove the law exam requirement for pharmacists desiring to become licensed via reciprocity from other states. The Board plans to pursue this statute change in FY25.
    - The Board will also pursue removal of AS 08.80.145(4) which has been identified as a barrier to licensure by reciprocity.
  - Allowing pharmacists to practice at the top of their clinical ability, education, training, and experience, including independent prescriptive authority.
    - The Board has identified that additional clarifications in AS 08.80.337 are needed to allow pharmacists to practice at the top of their clinical ability, education, training, and experience. The Board plans to pursue this statutes change again in FY25.
    - The healthcare system in general in Alaska has limited hospital beds, Emergency Department space, and other services in general. There needs to be a collaborative effort for all disciplines to practice at the top of scope to help address access for Alaskans.
  - Statutory Priorities Continued from FY24 into FY25 include:
    - Optimizing use and efficacy of the PDMP (AS 17.30.200)
    - Statutory changes to expand and optimize pharmacists' independent prescriptive authority (AS 08.80.337)
    - Review and update of Title 17 (Food and Drugs), specifically pharmacy-related changes needed in AS 17.20. AS 17.20.105 Part B has a line for therapeutic substitution allowing a pharmacist to substitute a product that is approximately equal in therapeutic value if the provider is not available and if the pharmacist notifies the provider.
    - AS 08.80.030(b)(18)-(Powers/Duties of the Board): establish standards for white/brown bagging: specific language “for a prescription drug that the United States Food and Drug Administration or the prescription drug's manufacturer has been not approved for self-administration, prohibit, limit, or provide conditions relating to the dispensing of the prescription drug, including establishing specifications to ensure the effectiveness and security of a prescription drug to be administered by infusion or otherwise administered in a clinical setting.”
- Regulatory Changes Needed:
  - \*Additional regulatory changes may be needed to align with the standard of care regulatory model concept implemented in January 2024.

**Alaska Board of Pharmacy  
FY 2024 Annual Report**

**Needs**

- **Additional Needs in FY25:**

\*Administrative support to reconvene the Controlled Substance Advisory Committee (CSAC). No meetings were held in FY23 or FY24. The Board of Pharmacy public member serving on the committee resigned and was replaced in FY23, and this role continues to serve as the chair of the CSAC. However, due to administrative challenges and competing demands within the Department of Law, this group has not yet been reconvened.

\*Prescription Drug Monitoring Program- collaboration facilitated by CBPL is needed among the professional boards regulated by the PDMP and others with a shared interest. Background: HB 306 (32<sup>nd</sup> Legislature) extended the Board of Pharmacy through June 30, 2028. While not the full eight (8)-year period that would have extend the board through 2030, the six (6)-year extension is necessitated by the need to reassess the administration and oversight of the Prescription Drug Monitoring Program (PDMP), the state's controlled substance prescription database and interactive technological tool to assist providers in combating the opioid epidemic. As the PDMP affects a total of five (5) professions regulated by the State Medical Board, Board of Nursing, Board of Examiners in Optometry, Board of Dental Examiners, and the Board of Pharmacy, the legislature expects to see continued collaboration among these boards and their constituents. The sunset audit also illuminated inherent statutory limitations that impose challenges on the Board of Pharmacy's ability to satisfy reporting requirements to the legislature and its ability to comply with federal grant deliverables. At the request of the legislature, DCCED - CBPL is procured a consultant in FY23 to analyze the structure of the PDMP, assess effectiveness of program administration and regulation, and to provide recommendations on how the system can better align with its legislative intent to support judicious prescribing and reduce diversion and abuse of federally-scheduled controlled substances. The consultant report completed by the McKinley Research Group (MGR) and released in February 2023 recommended CBPL convene a PDMP working group to review the findings of the analysis and prioritize changes for improved effectiveness through a multi-perspective lens. MGR noted that nature of this effort is beyond the scope or capacity of just the Board of Pharmacy itself and/or other healthcare licensure boards. Based on the Centers for Disease Control and Prevention (CDC) framework for PDMP Use/Effectiveness, it is recommended the working group be comprised of representatives from the PDMP program, state health department (i.e., Chief Medical Officer), state insurance programs (i.e., Medicaid Medical Director), healthcare licensure boards, and law enforcement. This workgroup has not yet been convened, and the Board of Pharmacy looks forward to participating in preparation for the next sunset audit.

\*Continued delegation of administrative tasks to Board of Pharmacy Executive Administrator position.

\*Board member training, engagement, and development including the concept of Just Culture.



# ALASKA BOARD OF PHARMACY

## TASK LIST - ACTION ITEMS

(as of 01/27/2025)

<b>Outstanding Action Items from Previous Meetings</b>	
	Task for Ashley Schaber to get letter in for national legislation. <b>Hold for next administration.</b>
	Task created for Michael Bowles to review the self-inspection form for updated regulations and bring the pharmacy inspection form into alignment with the self-inspection form.
	Task created for Michael Bowles to update all inspection forms for pharmacies and facilities.
	Task created for Michael Bowles to follow up on PDMP workgroup plan and timeline as recommended by the McKinley Group assessment.

<b>Action Items from November 14, 2024 Meeting</b>	
	Task for Michael Bowles to follow up on the CSAC and when they may be meeting.
	Task for Michael Bowles to reach out to the Executive Administrators for the board of nursing and medical board and discuss standard of care model, regulatory guidelines.
	Task for Michael Bowles to meet with Lisa Sherrell and discuss the board's perspective of looking at PDMP from a standard of care model and provide guidance on regulation changes that may be needed.
	Task for Michael Bowles to post the CQI FAQs to the website
	Task created for Michael Bowles to write draft language to address license requirement for changes to name, ownership, and physical location.
	Task created for all board members to review the statute and regulations to work on standard of care regulatory language changes.

	Not Started
	In Process
	Complete

# Alaska Board of Pharmacy

## Agenda Item #14



## Chair Final Comments

# Alaska Board of Pharmacy

## Agenda Item #15



Adjourn